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2 Abbreviations 
 
2-OG    2-oxoglutarate 
3-AP    3-aminopyridine-2-carboxaldehyde thiosemicarbazone 
ADP    adenosine diphosphate  
AIF    apoptosis-inducing factor 
AML    acute myeloid leukemia 
Arch    archazolid 
ATM    ataxia telangiectasia mutated 
ATP    adenosine triphosphate 
Bax    Bcl-2-associated X protein 
Bcl-2    B-cell lymphoma 2 
Bcl-xL    B-cell lymphoma extra large 
Bid    BH3-interacting domain death agonist 
BNIP3    Bcl-2/adenovirus E1B 19kDa interacting protein 3 
CAIX    carbonic anhydrase IX 
Caspase   cysteine-dependent aspartate-specific protease 
CDK1    cyclin-dependent kinase 1 
CO    control 
CREB    cyclic AMP response element-binding 
DBZ    dibenzazepine 
dCTP    deoxycytidine triphosphate 
DFO    deferoxamine 
DMSO   dimethyl sulfoxide
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DMT1    divalent metal transporter 1 
dNTP    deoxyribonucleotide triphosphate 
Doxo    doxorubicin 
DSB    double-strand break 
DTT    dithiothreitol 
ECM    extracellular matrix 
EDTA    ethylenediaminetetraacetic acid 
EEA1    early endosome antigen 1 
EGF    epidermal growth factor 
EGFR    epidermal growth factor receptor 
EGTA    ethylene glycol tetraacetic acid 
ErbB2    human epidermal growth factor receptor 2 
EV    empty vector 
FACS    fluorescence-activated cell sorting 
FAK    focal adhesion kinase 
FCS    fetal calf serum 
FeCit    iron citrate 
Glut1    glucose transporter 1  
GSI    γ-secretase inhibitor 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Hes1    hairy and enhancer of split 1 
Hey1/2   hairy and enhancer of split related with YRPW motif 1/2 
HIF1α    hypoxia-inducible factor 1α
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HRP    horseradish peroxidase 
IAP1/2   inhibitor of apoptosis 1/2 
IGFBP3   insulin-like growth factor-binding protein 3 
LAMP1/3   lysosomal-associated membrane protein 1/3 
LDL    low density lipoprotein 
LDLR    low density lipoprotein receptor 
LMP    lysosomal membrane permeabilization 
MCT    monocarboxylate transporter 
MDM2   mouse double minute 2 
MDS    myelodysplastic syndrome 
MEF    mouse embryonic fibroblasts 
MES    2-(N-morpholino)ethanesulfonic acid 
MSA    methanesulfonic acid 
mTOR    mammalian target of rapamycin 
mTORC1   mammalian target of rapamycin complex 1 
NAADP   nicotinic acid adenine dinucleotide phosphate 
NADP    nicotinamide adenine dinucleotide phosphate 
Ned-19   trans-Ned-19 
NHE1    Na
+
/H
+ 
exchanger 1 
NICD    notch intracellular domain 
NRARP   notch-regulated ankyrin repeat protein 
NT    non-targeting 
OXPHOS    oxidative phosphorylation
Abbreviations  II  
 
PARP    poly ADP ribose polymerase 
PBMC    peripheral blood mononuclear cell 
PBS    phosphate-buffered saline 
PDGFRβ   platelet-derived growth factor receptor β 
PDX    patient-derived xenograft 
PFA     paraformaldehyde 
PHD    prolyl hydroxylase 
PI    propidium iodide 
PI(3,5)P2   phosphatidylinositol 3,5-bisphosphate 
PMSF    phenylmethylsulfonyl fluoride 
Rb    retinoblastoma 
RNR    ribonucleotide reductase 
SD    standard deviation 
SEM    standard error of the mean 
T-ALL   T-cell acute lymphoblastic leukemia 
Tet    tetrandrine 
Tf    transferrin 
TfR    transferrin receptor 
TIGAR    TP53-induced glycolysis and apoptosis regulator 
TPC    two-pore channel 
TRP    transient receptor potential 
TRPML1   transient receptor potential mucolipin 1 
V-ATPase   vacuolar-type ATPase
Abbreviations  II  
 
VEGF    vascular endothelial growth factor 
VHL    von Hippel-Lindau 
XIAP    X-linked inhibitor of apoptosis  
γH2AX   phosphorylation of the H2AX histone 
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4 Summary 
 
Fighting cancer is one of the big challenges of this century. The success of today’s anti-cancer 
agents is limited by a variety of resistance mechanisms against the majority of 
chemotherapeutics. Moreover, it is dependent on the existence of metastasis. Overcoming 
these restraints by addressing new targets and by developing new treatment strategies is 
therefore highly appreciated.  
In recent years, targeting the endolysosomal machinery in cancer cells has come into focus as 
a promising anti-tumor approach. Preserving the balance between endocytic internalization 
and recycling of extracellular material, receptors, ligands and plasma membrane proteins is 
substantially required to control cellular processes such as signal transduction, nutrient 
uptake, cell adhesion and migration. Hence, disturbing endocytosis might be a promising 
strategy to interfere with pro-survival mechanisms, especially in fast proliferating and high 
metabolic active cancer cells.  
To this end, we here addressed two endolysosomal proteins to unveil their roles in cancer 
cells: the vacuolar-type ATPases (V-ATPases) and two-pore channels (TPCs). The V-ATPase 
is a multisubunit proton pump located in the membranes of endosomes and lysosomes, which 
actively transports protons into the lumen. Inhibition of these pumps was shown to induce 
apoptosis in different cancer cells before, however the precise mechanism stayed unclear. To 
investigate this matter, we used the myxobacterial V-ATPase inhibitor archazolid. Our first 
study (manuscript I, Cancer Research, 75(14):2863–2874) confirmed a strong cell death 
induction in the breast cancer cell lines MCF7 and MDA-MB-231 and showed induction of 
the hypoxia-inducible factor 1α (HIF1α) after archazolid treatment. Considering that HIF1α 
gets not only stabilized under hypoxia but also under iron depletion has led to experiments 
with excessive iron citrate in the cell culture medium which showed a complete abolishment 
of HIF1α stabilization and diminished cell death induction. The lack of cytosolic iron after 
archazolid treatment could be attributed to disturbed transferrin (Tf)/transferrin receptor (TfR) 
recycling. As a consequence, the iron depletion led to S-phase cell cycle arrest, double-strand 
breaks and the induction of the tumor suppressor p53. Moreover, this study showed in vivo 
efficacy of archazolid in a 4T1 mouse model, however it was not successful in abrogating 
tumor growth completely. 
In a second study (manuscript II, Oncotarget), archazolid’s apoptosis-inducing capabilities 
were confirmed in leukemic cell lines and in patient derived xenograft (PDX) leukemic cells. 
Mechanistically, V-ATPase inhibition reduced the expression level of the anti-apoptotic
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protein survivin, contributing to archazolid-induced cell death since overexpression 
significantly diminished the amount of dead cells. In respect to the underlying mechanism, 
this study ties in with the above reported findings of manuscript I that archazolid led to S-
phase arrest by interfering with the iron metabolism in leukemic cells. Since survivin 
expression strongly depends on cell cycle, these results suggest that archazolid decreased 
survivin at the protein level by inducing S-phase arrest.  
As above mentioned, manuscript I unveiled only a moderate reduction of tumor burden in 
vivo for archazolid in breast cancer cells. Thus, we intended to improve this by a rational 
combination approach. Since manuscript I further showed that archazolid treatment led to p53 
stabilization in p53 wild type tumor cells, combination treatment within the p53 pathway 
seemed promising. To this end, combination of archazolid with the small molecule p53 
activator nutlin-3a (manuscript III) in different p53 wild type tumor cells resulted in 
synergistic cell death induction. Remarkably, these findings were recapitulated in a U87MG 
(U87) wild type p53 xenograft model as combination was more efficient in reducing tumor 
growth compared to single dose treatment. On a molecular level we found reduced glycolysis, 
since TP53-induced glycolysis and apoptosis regulator (TIGAR) mRNA levels were elevated 
and glucose uptake and glucose transporter 1 (Glut1) protein levels were diminished. 
Moreover, pro-apoptotic pathways including insulin-like growth factor-binding protein 3 
(IGFBP3) and Bcl-2-associated X protein (Bax) were activated by the combination treatment.  
In a different approach we addressed the endolysosomal system of cancer cells by targeting 
TPCs (manuscript IV). TPCs are recently identified nicotinic acid adenine dinucleotide 
phosphate (NAADP)- and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2)-sensitive Ca
2+
-
permeable outward channels located in the membrane of endosomes and lysosomes. Their 
impact on cancer has not yet been studied. For that reason, silencing of TPC1 and TPC2 
mRNA levels with siRNA significantly reduced adhesion, migration through pores and 
directed migration of T24 cancer cells. Pharmacological inhibition of TPCs by either trans-
Ned-19 (Ned-19) or tetrandrine was efficient in diminishing migration through pores in T24, 
HUH7 and 4T1 cells. Mechanistic studies revealed that β1-integrin trafficking is disturbed 
after Ned-19 treatment leading to accumulation in early endosome antigen 1 (EEA1)-positive
vesicles. This is suggested to be due to alterations in Ca
2+
 signaling since acidification of 
vesicles was not affected. As a consequence, invasive cancer cells were no longer able to form 
leading edges, which is substantially required for adequate migration. Finally, tetrandrine 
showed anti-metastatic efficacy in a 4T1-Luc dissemination assay in vivo, altogether 
suggesting a role for TPCs in cancer cell migration. 
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Taken together, targeting the endolysosomal system either by TPC or V-ATPase inhibition 
can apparently both impair adequate endocytic trafficking of receptors or signaling molecules 
as seen for TfR (manuscript I) and β1-integrin (manuscript IV). As a result, this triggers the 
induction of apoptosis in cancer cells or reduces their invasive phenotype (Figure 1). One 
might speculate that there could be a link between V-ATPases and TPCs, most notably 
because the positive inward currents of V-ATPase could be balanced by an outward flux 
through TPCs. Thus, this work unveils new insights into the role of V-ATPases and TPCs in 
tumors und renders them highly attractive new targets to combat this disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Proposed influence of V-ATPase and TPC inhibition on endocytosis pathways. A shows simplified 
endocytic trafficking of TfR and integrins under normal conditions. B displays disturbed internalization of TfR 
after V-ATPase inhibition leading to iron depletion in the cell. C depicts halted β1-integrin trafficking after 
inhibition of TPC function resulting in accumulation of β1-integrin in enlarged vesicles. 
 
In conclusion, we here provide evidence that hitting highly metabolic active and invasive 
cancer cells through interfering with endocytosis is effective in disturbing pro-survival 
processes. The success of this strategy might be explained by the fact that malignant cells 
have to accomplish a high turnover of signaling molecules and nutrients to enable fast 
proliferation and migration. Moreover, targeting a complex and essential machinery like the 
endocytic trafficking system might allow to elude escape mechanisms and is therefore an 
innovative anti-tumor approach. 
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5 Introduction 
5.1 Cancer and current treatment strategies 
 
Cancer remains a leading cause of death worldwide. Hence, treating this disease is one of the 
big challenges of this century, particularly because the burden is thought to increase in the 
future (1). Nonetheless, due to improvements in treatment and earlier diagnosis the survival 
rate for certain cancers has improved over the past 30 years. For example, the overall 5-year 
relative survival rate for female breast cancer patients has increased from 74.8% between 
1975 and 1977 to 90.3% between 2003 and 2009. However, it drops to 24.3% for patients 
with distant-stage breast cancer. The clinical treatment of cancers mainly implicates, 
dependent on the type and stage of the tumor, surgery, radiation and pharmacological therapy 
(2). As the development of tumors involves in most cancers four to seven independent 
mutations, pharmacological targeting of only one pathway is in many cases insufficient to 
combat this disease. Therefore, a change to multi-target therapeutics has occurred in recent 
years (3). Moreover, the success of today’s anti-cancer drugs is challenged by resistance 
mechanisms against a variety of chemotherapeutics (4). Thus, there is still an urgent need to 
find new targets and treatment strategies to fight cancer, especially for invasive malignancies 
homing to distant sites.  
5.2 Targeting the endolysosomal system of cancer cells 
 
The uptake of extracellular material, lipids, ligands and plasma membrane proteins into the 
cell is processed by endocytosis and is essential for fundamental cellular processes such as 
signal transduction (5). Endocytosed cargos are subsequently delivered to early endosomes, 
where the first sorting takes place. Here, distinct components, like house-keeping receptors, 
are recycled to the plasma membrane whereas others are trafficked to late endosomes for 
additional sorting or to lysosomes for degradation (6). There are several ways how 
endocytosis can occur for example in a clathrin-dependent or -independent manner. 
Prominent clathrin-dependent cargo proteins are the transferrin receptor (TfR) and the low 
density lipoprotein receptor (LDLR) (5). TfR for instance binds its ligand ferrotransferrin at 
the cell surface and is subsequently transported in clathrin-coated vesicles after recognition by 
adaptor proteins. After internalization of Tf/TfR, iron dissociates from the receptor-ligand 
complex and enters the cytosol whereas the complex gets recycled to the cell surface (7, 8) 
(Figure 2). Clathrin-independent endocytosis appears in various forms and needs to be further 
studied (5). Interestingly, some proteins can follow more than one internalization route as it 
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has been shown for integrin heterodimers, which are a family of adhesion molecules 
mediating the interaction between a cell and the extracellular matrix (ECM) (9). Preserving 
the balance between endocytic internalization and recycling is substantially required to 
control cellular processes such as signal transduction, nutrient uptake, cell polarity, cell 
adhesion and migration (5).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Endocytic trafficking pathways. The scheme depicts the transport of endocytic cargos upon 
internalization exemplified by trafficking of Tf/TfR and LDL/LDLR. After uptake in clathrin-coated pits, cargos 
are delivered to sorting endosomes and can be returned directly or recycled to the surface as shown for Tf/TfR or 
transported to early and late endosomes and finally to lysosomes for degradation as illustrated for LDL. Scheme 
designed and modified according to the model of Maxfield and MacGraw (10). 
 
To function as the cellular sorting and degrading network, the endolysosomal system 
establishes a pH gradient from 6.2 in early endosomes to 4.6 in lysosomes which allows for 
high activity of degrading enzymes and for receptor-ligand processing. The luminal acidic 
milieu is maintained by vacuolar-type ATPases (V-ATPases) which actively pump protons 
across the endolysosomal membrane generating a positive inside membrane potential. As this 
would quickly build a self-limiting electrochemical gradient, the flux of other ions is required 
(6). Hence, despite V-ATPases, diverse other ion channels are thought to function in the 
endolysosomal system of cells including Cl
-
 antiporters, K
+
/H
+
 exchangers, Na
+
/H
+
 
exchangers or Ca
2+
/H
+
 exchangers and Ca
2+
 channels (6, 11). Despite the mucolipins, which 
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represent members of the transient receptor potential (TRP) superfamily of Ca
2+
 channels, the 
two-pore channel (TPC) family has recently been identified as endolysosomal Ca
2+
 channels 
(6) (Figure 3). 
 
 
 
 
 
 
 
 
 
 
Figure 3 Overview of the main ionic influx and outflux mechanisms of an acidic organelle. Depicted is the 
V-ATPase, which pumps protons across the membrane into the lumen upon ATP hydrolysis, two families of 
voltage gated Ca2+ releasing channels: TPCs and the mucolipins, which are members of the TRP superfamily, the 
postulated Ca2+/H+ exchanger and a Cl-/H+ antiporter (ClC, Cl- channel). TPCs and mucolipins may additionally 
function as release channels for other cations (6, 11-13).  
 
In search for new promising cancer targets lysosomes came in focus. In the acidic milieu of 
these organelles hydrolases, such as cathepsins, are highly active in breaking down nucleic 
acids, proteins or lipids. Interestingly, after lysosomal membrane permeabilization (LMP) 
cathepsins can still function at cytosolic pH. Hence, recently it has been hypothesized that 
lysosomal cell death through LMP could be implicated in cancer and might therefore be an 
interesting target (14). However, secreted cathepsins in the extracellular space are of 
oncogenic character, suggesting the inhibition of this process as another promising anti-cancer 
strategy (15). Moreover, targeting the lysosomal pH by blocking V-ATPase in diverse cancer 
cell lines showed strong anti-tumor activity (16). Taken together, first studies revealed that 
addressing the endolysosomal machinery might be a very promising anti-cancer strategy. 
Nevertheless, further research is needed especially because the implication of other 
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endomembrane-associated proteins such as the TPCs has not yet been investigated in this 
context.  
5.2.1 The vacuolar-type ATPase 
 
As mentioned above, V-ATPases are proton pumps located in the membranes of endosomes 
and lysosomes of cells. In cancer cells they are additionally expressed at the plasma 
membrane (17), presumably to facilitate invasion of surrounding tissue by acidifying the 
microenvironment (18). The V-ATPase is a multisubunit enzyme organized into two 
functional domains: the cytosolic V1 and the membrane integral V0. The V1 complex is 
composed of eight different subunits and provides the energy for proton transport as it 
comprises three catalytic binding sites for the hydrolysis of ATP to ADP and a free 
phosphate. The V0 domain is required for proton translocation upon energy release and 
consists of the subunits a, c, d and e. In yeast, there are three possible isoforms for c: c, c´ and 
c´´. Mammalian V0 is lacking c´ but has an additional glycoprotein named Ac45. The released 
energy through ATP cleavage results in a conformational change in the catalytic A subunits 
effecting a rotational movement of the central shaft subunits D and F of V1, and d and the c-
ring of V0. Protons enter the lumen through the interaction of two proton conducting half 
channels in subunit a and an acidic amino acid side chain, located in each of the c subunits 
(19) (Figure 4). 
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Figure 4 Structure and function of the V-ATPase in yeast. The V-ATPase is composed of two major 
complexes V1 and V0: V1is extended to the cytoplasm and consists of eight subunits (A-H). The V0 complex is 
located within the membrane with its six different subunits (a, d, e and c, c`, c``). A conformational change of the 
subunit A, which is driven by ATP hydrolysis, results in the rotational movement of the central shaft subunits D 
and F of V1 and d and the c-ring of V0. Subunit a of V0 provides two proton conducting half channels. Protons 
can enter the first channel and bind to an amino acid side chain of one of the c subunits of V0. Rotation of the c-
ring of V0 translocates the proton to the second channel finally releasing it to the lumen. Illustrated according to 
the model of Jefferies et al. (19) and Inoue et al. (20). 
 
Due to its indispensable role in the endocytic pathway, V-ATPases are associated with a 
variety of normal cellular processes such as membrane and intracellular trafficking, 
degradation of macromolecules and acidification of secretory vesicles, which drives the 
transport of neurotransmitters like glutamate. Moreover, V-ATPase functions in diseases as it 
is implicated for instance in the endocytic entry of viruses into the cell (21). Interestingly, in 
the last decade evidence is increasing that V-ATPases might play a pivotal role in cancer 
cells. Reports show that human invasive pancreatic tumors overexpress V-ATPase (22) and it 
has been hypothesized that plasma membrane located V-ATPases are implicated in gaining an 
invasive phenotype in cancer cells (23). Pharmacological V-ATPase inhibition showed cell 
death induction in different cancer cell lines (24-26) and was less effective in non-tumor cells 
(16, 27). Although the cytotoxic effects of V-ATPase inhibitors have extensively been 
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studied, the precise mechanism still awaits molecular explanation. Researchers have 
hypothesized that inhibition of macroautophagy (24) or the release of proteases after 
lysosomal dysfunction might play a role (25). In another approach, inhibition of V-ATPase 
was efficient in reducing migration of invasive cancer cells in vitro and in vivo. This work 
further unveiled effects on receptor recycling after block of V-ATPase function since 
epidermal growth factor receptor (EGFR) internalization was delayed (28). A contribution of 
V-ATPase to receptor trafficking was also observed in another study (29).  
A lot of the recent knowledge about V-ATPases has been gained by using pharmacological V-
ATPase inhibitors. The oldest members, bafilomycin and concanamycin, have already been 
identified in the early 1980s (30). They are plecomacrolides and inhibit V-ATPase function 
by binding to subunit c of V0 with a minor contribution of subunit a to the binding site. A 
novel very interesting player in this field is the myxobacteria-derived archazolid. It is 
produced by Archangium gephyra and Cystobacter violaceus and the main structural features 
are a macrocyclic lactone ring with a thiazole side chain (Figure 5). Archazolid interacts with 
subunit c of V0 as it competes with concanamycin for its binding site (30). However, 
archazolid’s binding site is located within the equatorial region of the V0 rotor subunit c and 
not at the interface of two adjacent c subunits as it is for plecomacrolides (31). First studies 
revealed anti-cancer activity for archazolid (16, 28, 32), suggesting further research to 
elucidate a potential implication in cancer therapy. 
 
Figure 5 Structure of archazolid A and archazolid B. Chemical structure adapted from Roethle et al. (33) 
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5.2.2 Two-pore channels 
 
The very first evidence for the existence of a vacuolar located ATPase was given in 1962 and 
this was confirmed by diverse studies until the early 1980s (34). The identification of 
endolysosomal TPCs happened much later. There was emerging evidence at the beginning of 
this century that nicotinic acid adenine dinucleotide phosphate (NAADP) is a Ca
2+
 mobilizing 
messenger and that it addresses stores separate from the endoplasmic reticulum in acidic 
organelles. However, the precise target was unclear. NAADP displays a high structural 
similarity to nicotinamide adenine dinucleotide phosphate (NADP) despite the carboxyl group 
at position 3 of the pyridine (35). Recently, TPCs have been identified as the long-sought 
endolysosomal NAADP-dependent Ca
2+
 release channels (36-38). TPCs are assigned to the 
superfamily of voltage-gated ion channels. Their postulated structure implicates a two-fold 
symmetry with six putative transmembrane α-helices each (36, 39). It has been suggested that 
TPC channels form homo- and heterodimers (40) (Figure 6). Up to now there are three TPC 
genes identified in sea urchins and most vertebrates: TPC1, TPC2 and TPC3, however TPC3 
is not present in most primates (36).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Membrane topology of TPCs. Depicted is the predicted transmembrane organization of TPCs with 
two putative pore-forming repeats containing six transmembrane segments and an intervening pore-loop between 
segment 5 and 6. Upper panel shows the postulated composition of the native TPC channel consisting of two 
TPC monomers forming a dimer. Illustrated according to Zhu et al. (12). 
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Diverse studies revealed that TPC1 and TPC2 are located in the endolysosomal system of 
cells with TPC1 expressed in endosomes and lysosomes whereas TPC2 can predominantly be 
found in lysosomes (36-38, 40, 41). Although most researchers claimed that activation of 
TPCs is triggered by NAADP (36-38, 42-44), it has also been suggested that 
phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2) is implicated (43, 45). Independent 
experiments hypothesized TPCs as Ca
2+
 channels, suggesting them responsible for Ca
2+
 
release from endolysosomal stores (36, 38, 42, 44), albeit conductance for Na
+
 was also 
discussed (45).  
 
Given the fact that TPCs are located in endosomes and lysosomes, it does not come as a 
surprise that they function in the endocytic pathway. Reports show that overexpression of 
TPC2 inhibits autophagosomal-lysosomal fusion (46) and that they are crucially involved in 
the regulation of endolysosomal trafficking. Thus, TPC2 deficient mouse embryonic 
fibroblasts showed accumulation of EGF/EGFR and LDL in intracellular vesicles (47) and 
delayed platelet-derived growth factor receptor β (PDGFRβ) degradation (48). Moreover, 
cholera toxin, which is under normal conditions trafficked to the Golgi, was halted in 
endolysosomes after overexpression of TPCs (41). Disturbed TPC function retained Ebola 
virus trafficking, which prevented host cell infection (49). Despite effects on endocytic 
trafficking, TPCs were recently connected to lysosomal control of nutrient recycling. It was 
hypothesized that TPCs form a lysosomal ATP-sensitive Na
+
 channel complex which is 
associated with and regulated by the mammalian target of rapamycin (mTOR). Under 
starvation mTOR delocates from the complex resulting in release of Na
+
 and other ions from 
lysosomes (50). Interestingly, V-ATPase was also identified as a component of the mTOR 
pathway. It has been postulated that V-ATPase is crucial for amino acid signaling to mTOR 
complex 1 (51). Given the fact that TPCs and V-ATPases are both implicated in endocytic 
trafficking and mTOR signaling, one might speculate that there could be a link between these 
two proteins, most notably because the positive inward currents of V-ATPase could be 
balanced by an outward flux through TPCs.  
 
To target the TPC pathway pharmacologically the NAADP antagonist Ned-19 was used in 
different studies (46, 49, 52). Ned-19 was identified as a noncompetitive antagonist of 
NAADP by virtual screening, with the trans form more potent than the cis form regarding 
Ca
2+
 release (53). In addition, lately, the bis-benzylisoquinoline alkaloid tetrandrine was 
reported to block TPC-mediated currents elicited by NAADP and PI(3,5)P2 (49), however it 
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might act on other Ca
2+ 
channels as well (54). Tetrandrine can be purified form the root of 
Stephania tetrandra and has been used in traditional chinese medicine for instance against 
hypertension (54) (Figure 7).  
 
 
 
Figure 7 Structure of trans-Ned-19 and tetrandrine. Chemical structure of trans-Ned-19 adapted from Naylor 
et al. (53). Chemical structure of tetrandrine adapted from Inubushi et al. (55). 
 
Although in some studies cancer cell lines were used as a cellular system to investigate TPC 
function, its implication in cancer progression, cancer cell migration and formation of 
metastasis has not been studied up to now. Therefore, it would be highly interesting to 
investigate this matter to elucidate a potential role in cancer treatment.  
5.3 Overcoming the hallmarks of cancer 
 
The development of a normal cell into a malignant cancer cell requires in most cases four to 
seven mutations (3). These mutations allow cancer cells to behave different to normal cells. 
For cancer therapy it is highly appreciated to find treatment strategies which mainly target 
malignant cells to reduce side effects. To achieve this, it seems promising to address the 
altered behavior of cancer cells. 
 
In 2000, Hannahan and Weinberg defined the hallmarks of cancer describing the gained 
abilities of malignant cells. One is to evade apoptosis (56). Apoptosis, the programmed and 
controlled cell death, occurs during development or aging but is also a defense mechanism for 
instance when cells are damaged by noxious agents. Morphologically, apoptosis starts with 
cell shrinkage and chromatin condensation which is followed by plasma membrane blebbing 
and subsequent separation of cell fragments into apoptotic bodies. Degradation of these 
bodies occurs finally by phagocytosis through macrophages. Induction of apoptosis can be 
triggered by a variety of signals. Mechanistically, there are two main apoptotic pathways: the 
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intrinsic and the extrinsic. The intrinsic pathway is for example stimulated by radiation, toxins 
or hypoxia. These stimuli cause mitochondrial changes effecting an opening of the 
mitochondrial permeability pore and release of pro-apoptotic proteins such as cytochrome c. 
These processes are regulated by members of the B-cell lymphoma 2 (Bcl-2) family such as 
Bcl-2 or Bcl-2-associated X protein (Bax). The release of pro-apoptotic proteins from 
mitochondria triggers the formation of the apoptosome and activation of caspase-9. The 
extrinsic pathway is activated by the binding of a death ligand such as Fas ligand to its 
receptor which results in formation of the death inducing signaling complex, finally activating 
caspase-8. Both pathways converge in the activation of caspase-3 which initiates the 
degradation of the chromosomal DNA (57). Cancer cells are often resistant to apoptosis and 
self-sufficient in growth signals, another gained ability (56), which enables uncontrolled and 
fast proliferation. Overcoming these hallmarks of cancer by pharmacological induction of 
apoptosis is therefore a viable strategy for cancer therapy, albeit its contribution to treatment 
success was questioned. Therefore, investigating non-apoptotic types of cell death might be 
an alternative anti-cancer approach (58).  
 
Despite evading apoptosis, cancer cells gained the ability to migrate and invade which allows 
for pulling themselves forward into new tissues to build metastasis (56). The formation of 
growth at secondary sites starts with the acquisition of an invasive phenotype of the primary 
tumor. Then, some tumor cells detach and intravasate to enter hematogenous circulation 
which is followed by extravasation into the new tissue. There, the tumor cell adapts to the 
foreign site and initiates proliferation. Since as much as 90% of cancer-related mortality is 
due to metastasis, new strategies to improve the treatment of invasive cancers remain of 
interest to develop (59). 
 
In order to enable fast proliferation and migration, cancer cells have to be highly metabolic 
active. Therefore, malignant cells established an altered turnover of signaling molecules (60) 
and a rapid uptake of nutrients which allows tumor imaging in the clinic (61). Thus, derailed 
endocytosis was described as an emerging multifaceted hallmark of these cells (60). In turn, 
targeting the endocytic machinery pharmacologically might be a highly promising strategy to 
selectively hit cancer cells. Moreover, addressing this tumor-essential process could be an 
innovative approach to elude escape mechanisms. 
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6 Aim of the study 
 
Cancer remains one of the leading causes of death worldwide. The success of today’s anti-
cancer drugs is challenged by a variety of resistance mechanisms against the most 
chemotherapeutics and by the occurrence of metastasis. Thus, new targets and treatment 
strategies are urgently needed. Previous work of our group revealed targeting the 
endolysosomal vacuolar-type ATPase as a promising future anti-cancer approach as it induces 
apoptosis in cancer cells. However, the precise mode of action still awaits molecular 
explanation.  
 
Hence, the aim of this study was to elucidate this matter and to extend the previous data for in 
vivo efficacy including rational combination therapy. Moreover, the question was addressed 
whether targeting the endolysosomal system by inhibition of two-pore channels might be a 
new and viable approach for the treatment of invasive tumor cells.  
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7 Short summary of manuscripts 
7.1 Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects 
in breast cancer 
Lina S. Schneider, Karin von Schwarzenberg, Thorsten Lehr, Melanie Ulrich, Rebekka 
Kubisch-Dohmen, Johanna Liebl, Dirk Menche and Angelika M. Vollmar 
2015, Cancer Research, 75(14):2863–2874 
Within the last decade evidence is increasing that the vacuolar-type ATPase (V-ATPase), a 
heteromultimeric proton pump, plays a vital role in the survival of tumor cells. However, the 
precise mode of action still awaits molecular explanation. To investigate V-ATPase mediated 
cytotoxicity we used the myxobacteria-derived compound archazolid, a highly potent V-
ATPase inhibitor. While V-ATPase inhibitors showed anti-tumoral potential in diverse cancer 
cell lines, in vivo data are limited up to now. Our study showed for the first time reduced 
tumor growth in a 4T1 mammary mouse model. With regard to the molecular mechanisms of 
V-ATPase-related cell death, we found that archazolid stabilizes the hypoxia-inducible factor 
1α (HIF1α) protein in the two breast cancer cell lines MCF7 and MDA-MB-231. As HIF1α 
has many target genes involved in glycolysis, we could detect elevated levels of the 
hexokinase II protein as well as of other glycolytic gene products such as aldolase c. Further 
experiments unveiled that the HIF1α stabilization is due to iron depletion in the cytosol since 
an excess of iron citrate in the medium abolished it completely. Moreover, the lack of iron is 
partially responsible for the induction of cell death after V-ATPase inhibition and could be 
associated with disrupted transferrin/transferrin receptor internalization upon V-ATPase 
inhibition. As a consequence, activity of the iron dependent enzyme ribonucleotide reductase 
is diminished leading to S-phase block and double-strand breaks. Additionally, in p53 wild 
type MCF7 cells protein levels of the tumor suppressor p53 were elevated after archazolid 
treatment, which contributed to the induced cell death since pifithrin-α diminished 
significantly the amount of dead cells. These findings eventually connect V-ATPase 
inhibition to fundamental cellular processes such as DNA synthesis and DNA repair. Hence, 
our study reveals a novel mode of action for V-ATPase-induced cell death in tumor cells and 
proposes V-ATPase inhibition as a promising and viable strategy for breast cancer therapy.  
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7.2 Anti-leukemic effects of the V-ATPase inhibitor Archazolid A 
Siwei Zhang, Lina S. Schneider, Binje Vick, Michaela Grunert, Irmela Jeremias, Dirk 
Menche, Rolf Müller, Angelika M. Vollmar and Johanna Liebl 
2015, accepted for publication in Oncotarget  
The V-ATPase inhibitor archazolid showed promising anti-tumor effects in different cancer 
cell lines as for example demonstrated in manuscript I. Since new treatment strategies for 
patients suffering from T-cell acute lymphoblastic leukemia (T-ALL) are urgently needed, we 
elucidated archazolid’s potential as an anti-leukemic drug. Indeed, V-ATPase inhibition 
triggered induction of apoptosis in leukemic cell lines which could be shown by flow 
cytometry analysis, cleavage of caspase-3, caspase-9 and poly ADP ribose polymerase 
(PARP). Along this line, archazolid treatment in patient derived xenograft (PDX) leukemic 
cells, but not in non-tumor primary human peripheral blood mononuclear cells, resulted in 
induction of cell death. Mechanistically, by inhibiting lysosomal acidification, archazolid 
reduced activation of the notch pathway as the expression of notch1 intracellular domain 
(NICD) and of the downstream target c-myc were diminished. However, NICD 
overexpression was not able to rescue archazolid-mediated cell death, suggesting further 
studies regarding the underlying mechanisms. In fact, V-ATPase inhibition by archazolid 
decreased the expression level of the anti-apoptotic protein survivin. Remarkably, its 
overexpression significantly diminished the amount of dead cells during V-ATPase inhibition 
providing evidence for its implication in archazolid-induced cell death. Regarding the 
underlying mechanism, this work ties in with our previous findings of manuscript I that 
archazolid led to S-phase cell cycle arrest by interfering with the iron metabolism in leukemic 
cells. Thus, this study renders V-ATPases as potential new targets for the treatment of T-ALL.  
Declaration of contribution: I contributed to this work of Dr. Siwei Zhang and Dr. Johanna 
Liebl by conducting a set of experiments including FACS and western blot analysis of PDX 
leukemic cells, cell cycle analysis of Jurkat cells and PCR analysis of Jurkat cell samples. I 
was partially involved in the design of the study since the investigated underlying mechanism 
is associated with my earlier work (manuscript I).   
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7.3 MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition 
Lina S. Schneider, Melanie Ulrich, Thorsten Lehr, Dirk Menche, Rolf Müller, 
Angelika M. Vollmar and Karin von Schwarzenberg 
Submitted 
The anti-cancer potential of the V-ATPase inhibitor archazolid has been proven in distinct in 
vitro studies, however in vivo data are rare. Manuscript I showed first promising in vivo 
efficacy of archazolid in a 4T1 mouse model, albeit tumor growth was not abrogated 
completely. To improve this matter, we searched for a rational and innovative combination 
strategy. As tumors often carry several mutations, using multiple drugs targeting different 
proteins seems therefore more beneficial for cancer treatment. Since our recent study 
(manuscript I) unveiled that inhibition of V-ATPase caused the induction of p53 protein levels 
in cancer cells, we considered a combination strategy within the p53 pathway. In fact, in this 
study we found that combining archazolid with the p53 activator, nutlin-3a, induces 
synergistically cell death in different p53 wild type tumor cell lines, but not in p53 mutated 
cells, as shown by flow cytometry analysis. Investigating the underlying mechanism, we 
could detect reduced glycolysis as TP53-induced glycolysis and apoptosis regulator (TIGAR) 
mRNA levels were elevated and glucose uptake, glucose transporter 1 (Glut1) protein levels 
and ATP levels were decreased by the combination. Moreover, treatment of archazolid and 
nutlin-3a activated pro-apoptotic pathways involving the induction of insulin-like growth 
factor-binding protein 3 (IGFBP3) and active Bcl-2-associated X protein (Bax) and the 
cleavage of caspase-9 and PARP. Finally, combination treatment was more efficient in 
reducing tumor growth compared to single dose treatment in a p53 wild type U87MG 
glioblastoma xenograft. Especially the success of archazolid and nutlin-3a in vivo suggests 
this combination as a potential new therapeutic option for p53 wild type carcinomas.  
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7.4 Two-pore channel function is crucial for migration of invasive cancer cells 
Lina S. Schneider*, Christian Grimm*, Yu-Kai Chao, Anna Watermann, Melanie 
Ulrich, Doris Mayr, Christian Wahl-Schott, Martin Biel* and Angelika M. Vollmar* 
*These authors contributed equally to this work 
Submitted 
The most cancer-related deaths are caused by metastasis. Spread of single tumor cells to 
anatomically distant sites requires the ability to migrate and invade. Disrupting these 
processes is therefore thought to be a promising strategy for the treatment of invasive 
carcinomas. As targeting the endocytic system by V-ATPase inhibition was effective in 
reducing cancer cell migration before, we here investigated the impact of endolysosomal two-
pore channels (TPCs) in this context. TPCs are recently identified nicotinic acid adenine 
dinucleotide phosphate (NAADP)- and phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2)-
sensitive Ca
2+
-permeable ion channels located in the membrane of endosomes and lysosomes. 
Their implication in cancer cell progression and migration has not been studied up to now. To 
this end, siRNA silencing of TPC1 and TPC2 mRNA levels in T24 cancer cells resulted in 
reduced adhesion, migration through pores and directed migration. Along this line, 
pharmacological inhibition of TPC function through Ned-19 and tetrandrine inhibited 
migration through pores in T24, HUH7 and 4T1 cancer cells. Mechanistically, we found that 
disturbing TPC function affected β1-integrin trafficking, causing accumulation in early 
endosome antigen 1 (EEA1)-positive vesicles. This is suggested to result from alterations in 
Ca
2+
 signaling since acidification of vesicles was not inhibited. Finally, trans-Ned-19-treated 
cells showed insufficient formation of leading edges, which is crucial for adequate migration. 
Remarkably, these effects were recapitulated in a mouse model of tumor dissemination 
showing significantly reduced lung metastasis of 4T1-Luc cells after tetrandrine treatment. 
Thus, this study identified TPCs as new and interesting candidates to address in the treatment 
of invasive cancer cells. Once more, targeting the endolysosomal system of cancer cells seems 
to be a promising anti-cancer approach.  
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Vacuolar-ATPase Inhibition Blocks Iron
Metabolism to Mediate Therapeutic Effects
in Breast Cancer
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Kubisch-Dohmen1, Johanna Liebl1, Dirk Trauner3, Dirk Menche4, and Angelika M.Vollmar1
Abstract
Generalized strategies to improve breast cancer treatment
remain of interest to develop. In this study, we offer preclinical
evidence of an important metabolic mechanism underlying the
antitumor activity of inhibitors of the vacuolar-type ATPase
(V-ATPase), a heteromultimeric proton pump. Speciﬁcally, our
investigations in the 4T1 model of metastatic breast cancer of the
V-ATPase inhibitor archazolid suggested that its ability to trigger
metabolic stress and apoptosis associated with tumor growth
inhibition related to an interference with hypoxia-inducible fac-
tor-1a signaling pathways and iron metabolism. As a conse-
quence of disturbed iron metabolism, archazolid caused S-phase
arrest, double-stranded DNA breaks, and p53 stabilization, lead-
ing to apoptosis. Our ﬁndings link V-ATPase to cell-cycle progres-
sion andDNA synthesis in cancer cells, and highlight the basis for
the clinical exploration of V-ATPase as a potentially generalizable
therapy for breast cancer. Cancer Res; 75(14); 2863–74. 2015 AACR.
Introduction
Breast cancer is a major health issue, which worldwide causes
almost 500,000 female fatalities each year, being the most lethal
cancer forwomen (1). Therefore. it is of utmost importance toﬁnd
new therapeutics to combat this disease. Nature is still one of the
most essential sources for new chemotherapeutics, as approxi-
mately 60% of the new agents discovered in the last decades were
classiﬁed as naturally derived or inspired (2). The myxobacterial
macrolide archazolid, which was ﬁrst isolated from Archangium
gephyra (3), is a highly potent vacuolar-type-ATPase (V-ATPase)
inhibitor (4). It showed ﬁrst promising cytotoxic effects on
diverse cancer cells lines (5, 6) proposing pharmacologic V-
ATPase inhibition as a new strategy to abrogate solid tumor
growth. However, the precise mode of action is not deﬁned yet.
V-ATPases are proton pumps located in the endomembrane
systemof eukaryotic cells aswell as in theplasmamembrane. They
are heteromultimeric enzymes consisting of two functional
domains: the cytosolic hydrolytic active V1 domain and the
membrane integral V0 complex, which is responsible for proton
translocation. V-ATPases actively transport protons from the
cytoplasm into intracellular compartments or across the outer
membrane. As a consequence of the acidiﬁcation of endosomes
and lysosomes, V-ATPases play a crucial role in the receptor-
mediated endocytosis and the endosomal trafﬁcking (7). Besides
a variety of transporter and channel proteins, plasma membrane
localized V-ATPase is reported to modulate the tumor microen-
vironment (7, 8). V-ATPase function can be inhibited by the
myxobacterial compound archazolid, which binds to subunit c
of the membrane integral V0 domain (4).
Our earlier studies revealed a strong cytostatic effect of arch-
azolid ondiverse cancer cell lines in vitro and showed an induction
of cellular stress response involving the stabilization of the
hypoxia-inducible factor 1 a (HIF1a) protein (6). Yet, it stayed
unclear how inhibition of V-ATPase generates HIF1a stabiliza-
tion. The aim of this study was now to illuminate this matter and
to extend the in vitro data for in vivo efﬁcacy. Thereby, we uncover
that V-ATPase inhibition impedes the iron metabolism of cancer
cells, which opens up new therapeutic options for V-ATPase
inhibitors.
This work unveils that the natural derived V-ATPase inhibitor
archazolid disrupts endocytotic transferrin receptor (TfR) recy-
cling, leading to iron depletion in the cytosol followed by stabi-
lization of the HIF1a protein and reduction of ribonucleotide
reductase (RNR) activity. Finally, this leads to induction of apo-
ptosis in vitro and reduction of tumor growth in vivo. These results
suggest V-ATPase as a highly promising target for breast cancer
treatment at the interplay of iron metabolism and apoptotic
processes.
Materials and Methods
Cell lines and reagents
Themammary cancer cell linesMDA-MB-231 cells were recent-
ly purchased from Cell Line Service Eppelheim, MCF7 from
DSMZ, and 4T1-Luc (4T1) from PerkinElmer. MCF7 cells were
grown in RPMI-1640 supplemented with 10% FCS, 1% pyruvate,
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1% nonessential amino acids, and 125 mg/L insulin. MDA-MB-
231 cells were cultured in DMEM High Glucose containing 10%
FCS and 4T1 cells in RPMI-1640 with 10% FCS. Archazolid was
synthesized by Prof. Dirk Trauner (Department of Chemistry,
Ludwig-Maximilians-University of Munich, Munich, Germany)
and isolated from Prof. Dirk Menche (Institute of Organic Chem-
istry, University of Bonn, Bonn, Germany), QVD was purchased
fromR&DSystems, ferric citrate, deferoxamine, 3-aminopyridine-
2-carboxaldehyde thiosemicarbazone (3-AP), doxorubicin, piﬁ-
thrin-a from Sigma Aldrich, and KU55933 from Santa Cruz
Biotechnology.
In vivo mouse model
Sixteen female BALB/cByJRj mice (Janvier) were locally
shaved and 2  106 4T1 cells were injected subcutaneously
into the ﬂank of each mouse. Mice were divided into two
groups and treated intravenously with 0.3 mg/kg archazolid
in 5% DMSO/10% solutol/PBS or equal amounts of 5%
DMSO/10% solutol/PBS. Mice were treated three times a week.
Measurement of tumors was done every 2 to 3 days with a
caliper, using the formula a  b2/2. The average tumor volumes
of the two groups were compared over time. Tumor volume was
modeled using a sequential exponential-linear growth model.
IHC analysis of tumor tissue sections was performed as
described previously (9) using anti-active-caspase-3-antibody
and Hoechst from Sigma. Modeling was performed using the
non-linear mixed effects modeling technique with the software
NONMEM 7.3 (10). Animal experiments were approved by the
District Government of Upper Bavaria in accordance with the
German animal welfare and institutional guidelines.
Western blot analysis
Protein lysis was performed as described before (6). Antibodies
givenbelowwere used:HIF1a (BectonDickinson),Hexokinase II,
PARP-1, gH2AX, p53, CREB (Cell Signaling Technology),
ATP6V0C (Novus), b-actin (Millipore), HRP-goat-antirabbit
(Bio-Rad),HRP-goat-antimouse (SantaCruzBiotechnology), and
AlexaFluor 680-goat-antirabbit (Invitrogen).
Cell transfection
For silencing experiments, 2  106 cells were transfected using
the Amaxa Nucleofector kit V (Lonza) program A-23. HIF1a and
ATP6V0C were silenced using ON-TARGETPlus SMARTpool
siRNA (2 mg) from Dharmacon and nontargeting siRNA as a
control.
Oxygen consumption assay
Oxygen consumption was analyzed with the MitoXpress-Xtra-
HS Kit (Luxcel Biosciences). A total of 8  106 MCF7 cells were
used. Phosphorescence signal was measured according to the
manufacturer's instructionswith SpectraFluor Plus reader (Tecan).
Measurement of metabolic activity
CellTiter-Blue Assay (Promega) was used according to the
manufacturer's instructions to measure metabolic activity.
Measurement of intracellular iron levels
For analysis of intracellular iron levels, cells were stained with
10 nmol/L calcein-AM (Santa Cruz Biotechnology) for 15 min-
utes. Fluorescence intensity was determined with FACSCalibur
(Becton). In addition, treated cells seeded on m-slides 8-well
ibidiTreat (IBIDI) were stained with 10 nmol/L calcein-AM for
15 minutes and analyzed by confocal microscopy.
TfR internalization assay
Cells seeded on m-slides 8-well ibidiTreat were starved for 2
hours. Subsequently, cells were incubated with transferrin (Tf)
-rhodamine conjugate (Invitrogen) for 15 minutes at 37C and
ﬁxed with 4% paraformaldehyde for 20 minutes. Cells were
mounted with PermaFluor mounting medium (Beckman Coul-
ter) and analyzedwith a Zeiss LSM510Meta confocalmicroscope
(Jena).
Mammospheres
MCF7 spheroids were grown using the hanging drop protocol
as described before (11).
Measurement of cell death and cell cycle
Cells were considered as dead when cell membrane was per-
meable for propidium iodide (PI; Sigma Aldrich). Trypsinized
and washed cells were resuspended in PBS containing 5 mg/mL PI
and analyzed by ﬂow cytometry. Cells with higher ﬂuorescence
intensities compared with control were examined as dead. To
quantify percentage of cells with sub-G1 DNA content, cell pellet
was resuspended in hypotonic-ﬂuorochrome solution containing
0.1%Triton X-100 and 50 mg/mL PI. Cells appearing left of G1
-peak were considered as apoptotic. In some experiments, cell
cycle was analyzed with FlowJo 7.6.
Clonogenic assay
Clonogenic assay was performed as described previously (6).
Measurement of dCTP levels
dCTP levels were measured as described previously (12).
Therefore, 3  106 cells were seeded on 10-cm culture dishes,
allowed to grow over night and treated for 24 hours.
qRT-PCR analysis
Total RNA was extracted using the RNeasy mini Kit (Qiagen
GmbH) according to the manufacturer's instructions. For cDNA
synthesis, the High Capacity cDNA Rerverse Transcription Kit
(Applied Biosystems) was used. qRT-PCR was performed with
the AB 7300 RealTime PCR system, the TaqMan Gene Expression
MasterMix (Applied Biosystems) and the SYBRGreen PCRMaster
Mix (Applied Biosystems) according to the manufacturer's
instructions. All designedprimerswere purchased fromMetabion.
ATP6V0C primers were purchased from Applied Biosystems.
Nuclei extraction
Stimulated MCF7 cells were trypsinized. Cell pellet was
resuspended in nuclear extraction buffer A (10 mmol/L HEPES,
pH 7.9, 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA,
1 mmol/L DTT, 0.5 mmol/L PMSF, 1 mmol/L Complete
EDTAfree; Roche) and incubated on ice for 15 minutes. Non-
idet P-40 (0.625%) was added, probes were vortex and
centrifuged. Pellet was resuspended in nuclear extraction buffer
B (20 mmol/L HEPES, pH 7.9, 0.4 mmol/L NaCl, 0.1 mmol/L
EDTA, 0.1 mmol/L EGTA, 1 mmol/L DTT, 0.5 mmol/L PMSF,
25% glycerol, 1 mmol/L Complete EDTAfree). After 15-minute
incubation on ice and centrifugation, supernatants were used
for Western blot analysis.
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Statistical analysis
GraphPad Prism Software was used for all statistical analysis.
Error bars indicate SEM. Synergism was calculated with the Bliss
formula: v ¼ xcombination/((xA  xB)  (xA  xB)), with v > 1
indicating synergism (13).
Results
Archazolid abrogates tumor growth in vivo and induces HIF1a
stabilization in vitro
To start with, archazolid was conﬁrmed to induce cell death in
breast cancer cell lines MDA-MB-231 and MCF-7 as well as in
mouse 4T1 cells (Supplementary Fig. S1). These results were
extended by an in vivomodel based on the 4T1 mouse mammary
tumor cell line to assess therapeutic relevance of V-ATPase inhi-
bition. In fact, archazolid reduced the tumor growth rate signif-
icantly with an average reduction of 24.4%, while the mean
mouse weight did not differ (Fig. 1A). Tumor tissues of arch-
azolid-treated mice showed induced caspase-3 activity (Fig. 1B).
To explore the molecular mechanism of archazolid-induced
cell death, the HIF1a protein came into focus. We conﬁrmed a
strongHIF1a expression after 24 hours of archazolid treatment in
MCF7 andMDA-MB-231 breast cancer cell lines (Fig. 1C). Impor-
tantly, silencing of ATP6V0C, the subunit c of V-ATPase, by siRNA
resulted in stabilization of HIF1a in both cell lines after 72 hours
(Fig. 1C), suggesting a V-ATPase–dependent effect. Silencing
efﬁciency is shown in Supplementary Fig. S2 both on the mRNA
andprotein level. In addition to the expression status of theHIF1a
protein, we analyzed themRNA levels via qPCR analysis in MDA-
MB-231 cells after 24 hours of treatment, which showed no
signiﬁcant changes (Supplementary Fig. S3), indicating an effect
on stabilization of HIF1a by archazolid.
As HIF1a has many target genes involved in glycolysis, we
investigated the impact of archazolid on glycolysis and oxidative
phosphorylation. Western blot analysis after 24 hours of arch-
azolid treatment showed induced hexokinase II protein levels in
breast cancer cell lines (Fig. 1D) as well as other glycolytic gene
products [6-phosphofructo-2-kinase/fructose-2, 6-bisphospha-
tase-3 (6PF2K3), aldolase C, Supplementary Fig. S4]. Moreover,
measurement of oxygen consumption demonstrated a reduction
inMCF7 cells after 4hours of archazolid treatment comparedwith
control cells (Fig. 1E). Oligomycin served as a positive control.
Interestingly, the ratio of metabolic activity of MCF7 cells grown
inmediumwith glucose to cells cultivatedwith galactose increases
after 48 hours of archazolid treatment further implicating a shift
to glycolysis (Fig. 1F). Galactose forces the cells to derive their
energy by oxidative phosphorylation. Hence, an increased ratio of
metabolic activity in glucose to galactose medium implicates a
mitochondrial impairment.
Iron depletion leads to HIF1a stabilization
To unveil how V-ATPase is implicated in HIF1a stabilization, it
is important to know that the hydroxylation of HIF1a by prolyl
hydroxylases (PHD) requires oxygen, 2-oxoglutarate and iron. To
examine whether a lack of iron is responsible for the stabilization
of HIF1a after V-ATPase inhibition, cell culture medium was
supplemented with iron citrate. Indeed, Western blot analysis of
breast cancer cells after 24 hours of treatment showed a complete
abolishment of archazolid-induced HIF1a stabilization in the
presence of additional iron (Fig. 2A). Hence, expression of HIF1a
is due to iron depletion in the cell.
Disruption of TfR recycling leads to iron depletion
To verify iron deprivation in the cytosol through V-ATPase
inhibition, confocal microscopy analysis was performed using
the ﬂuorescence dye calcein-AM. Of note, in MDA-MB-231
cells, the ﬂuorescence intensity increased after 24 hours of
high-dose archazolid treatment and could be compensated by
adding iron citrate to the medium (Fig. 2B). Flow-cytometric
analysis in calcein-AM–stained breast cancer cell lines after
24-hour treatment conﬁrmed these ﬁndings (Fig. 2C). Inter-
estingly, mRNA level of ferritin, a protein serving as an iron
storage in the cell as well as mRNA of transferrin and RRM2
were increased in MCF7 after 24 hours of archazolid treatment
and could be abolished by iron (Supplementary Fig. S5). To
further investigate the underlying mechanisms that lead to a
lack of cellular iron by V-ATPase inhibition, internalization of
TfR was analyzed. TfR binds Tf-bound iron and is taken up by
endocytosis. Tf-rhodamine conjugate was added and cells were
analyzed by confocal microscopy. Noteworthy, after 24 hours
of archazolid treatment recycling of Tf/TfR was disrupted in
breast cancer cells (Fig. 2D).
Iron depletion is responsible for archazolid-induced cell death
Next, we investigated whether iron depletion is responsible
for archazolid-induced cell death. Interestingly, ﬂow-cyto-
metric analysis of MCF7 and MDA-MB-231 cells after 48 hours
of archazolid treatment showed a reduction of PI-positive cells
when iron citrate was added (Fig. 3A). In addition, 4T1 cells
showed rescue of metabolic activity in medium with iron excess
(Supplementary Fig. S6). PARP-1 cleavage was abolished in
human breast cancer cell lines after 48 hours by adding iron
(Fig. 3B). Along this line, we could see a synergistic cell death
induction in MCF7 cells after 48 hours by combining arch-
azolid with the iron chelators deferoxamine and 3-AP (Fig. 3C).
In MDA-MB-231 cells, combination of archazolid and 3-AP led
to reduced formation of colonies after 24 hours of treatment
(Fig. 3D). We could verify these ﬁndings in three-dimensional
growing MCF7 mammospheres after 48 hours of treatment by
PI staining (Fig. 4A and B) and CTB assay (Fig. 4C).
Iron depletion leads to dysfunction of RNR
To more deeply analyze the consequences of archazolid-
induced iron depletion, we took a closer look at the iron-depen-
dent target RNR. The formation of deoxyribonucleotides (dNTP)
in a cell is iron dependent and catalyzed by RNR (14). For
analyzing RNR activity, dCTP levels were measured as described
previously (12). Interestingly, treatment of MCF7 and MDA-MB-
231 cells with archazolid for 24 hours resulted in reduced dCTP
levels in both cells lines (Fig. 5A). As dNTPs are needed for DNA
synthesis, cell-cycle analysis was examined in MDA-MB-231 cells
48 hours after archazolid treatment, showing S-phase block,
which could be rescued by adding iron (Fig. 5B). Phosphorylation
of the H2AX histone (gH2AX), indicating double-strand breaks
(DSB), was seen after 48 hours of archazolid treatment in all three
cell lines, further suggesting a reduced RNR activity after arch-
azolid treatment. Again, these effects were abolished by addition-
al iron (Fig. 5C and Supplementary Fig. S7). Combination of the
DNA intercalating drug doxorubicin with archazolid showed
reduced formation of colonies in MDA-MB-231 cells (Fig. 5D).
These ﬁndings connect V-ATPase inhibition to fundamental cel-
lular processes such as DNA synthesis and DNA repair.
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p53 is implicated in archazolid-induced cell death in p53
wild-type MCF7 cells
As the HIF1a protein and the occurrence of DSB are known
inducers of the p53 protein, we analyzed its implication in
archazolid-induced cell death in p53 wild-type MCF7 cells.
Figure 6A shows elevated p53 mRNA levels after 24 hours of
V-ATPase inhibition, which was compensated by additional iron.
Along this line, archazolid-treatedMCF7 cells indicate higher p53
protein levels after 48hourswithin thenucleus (Fig. 6B). Silencing
HIF1a in MCF7 cells reduced the induction of p53 protein levels
(Fig. 6C) revealing an impact of HIF1a on p53 expression in this
context. The ataxia telangiectasia mutated (ATM) kinasemediates
the induction of p53uponDSB. To unveil whether in addition the
presence of DSB elevates p53 protein levels, we used the ATM
inhibitor KU55933. Western blot analysis after 48 hours of
archazolid treatment in MCF7 cells indicates that this is the case
(Fig. 6D). Finally, to prove that p53 plays a role in archazolid
induced cell death, we used the p53 inhibitor piﬁthrin-a. Flow-
cytometric analysis of MCF7 cells after 48 hours shows a signif-
icant reduction of cell death in the presence of piﬁthrin-a (Fig. 6E)
providing evidence that p53 is involved in V-ATPase–dependent
cell death.
To sum up in a cartoon, Fig. 7 illustrates that V-ATPase inhib-
ition by archazolid leads to cell death induction, which ismediated
by iron depletion, resulting in the stabilization of the HIF1a pro-
tein and the inhibition of RNR together leading to p53 induction.
Discussion
Ourdata suggest V-ATPase as a highly interesting anddruggable
target to abrogate solid breast tumors by interfering with the iron
homeostasis of cancer cells.
Since theﬁrst advent of V-ATPase inhibitors, evidence is increas-
ing that V-ATPases are implicated in cancer. Reports show that
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V-ATPase is overexpressed in invasive pancreatic tumors (15) and
that the mass of V-ATPases located at the plasma membrane of
breast cancer cells correlates with their invasiveness (16). Among
various other transporter proteins such asmonocarboxylate trans-
porter (MTC), Naþ/Hþ exchanger (NHE1), carbonic anhydrase IX
(CAIX) plasma membrane located V-ATPase contribute to dysre-
gulated pH in the tumor microenvironment favoring tumor
progression and metastasis (8, 17). Moreover, overexpression of
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subunit c of V-ATPase in Drosophila induces a tumor-like tissue
transformation (18). Nontumor cells showed less cytotoxic
sensitivity toward V-ATPase inhibition compared with breast
carcinoma cells and hepatoblastoma cells (6, 19). It has been
shown that V-ATPase inhibition abrogates tumor cell migration
and dissemination through disturbed endocytotic activation of
Rac1 (20). Furthermore, cell death induction was observed in
various cancer cell lines by baﬁlomycin, a V-ATPase inhibitor
from the ﬁrst family (21–23). Consistently, we did ﬁnd induced
apoptosis in breast cancer cells through archazolid treatment.
Here, we could show for the ﬁrst time that V-ATPase inhibition
by archazolid reduced the growth rate of 4T1 mammary
tumors signiﬁcantly in vivo, indicating therapeutic relevance of
V-ATPase inhibition.
Although cell death induction through V-ATPase inhibition
was extensively studied, the precise causal mechanisms are still
not well understood. Wu and coworkers attributed the induction
of apoptosis in colon cancer by baﬁlomycin to the inhibition of
macroautophagy (21). Others suggested a mechanism in which
proteases are released after lysosomal dysfunction, leading to
caspase-3 activation (22). Our group postulated a mechanism
that involves the induction of a cellular stress response, including
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autophagy and the stabilization of HIF1a (6). This study here ties
in with our earlier work and reveals a role for V-ATPase at the
interplay of iron metabolism and apoptotic processes. Our ﬁnd-
ings illuminate that the cytotoxicity of V-ATPase inhibitors is
mainly due to disturbed TfR recycling, which impairs the iron
supply of cancer cells. As a consequence, the activity of iron-
dependent enzymes is reduced, leading to DSB, S-phase arrest,
and induction of p53.
In the last decades, it became more and more evident that
iron is implicated in cancer development. Induction of malig-
nant tumors by injecting iron dextran into rat was ﬁrst reported
in 1959 (24). This was conﬁrmed later by the observation that
patients injected with iron preparations developed sarcomas
(25). Consistently, epidemiologic reports from the 1980s asso-
ciated high body iron with the risk of cancer (26). The iron
supply of cancer cells is mainly mediated by the TfR. The clearly
deﬁned function of the TfR is the interaction with the iron
loaded plasma glycoprotein Tf initiating its endocytotic up take
(27). Since it has been reported that TfR is overexpressed in
cancer cells (28, 29), targeted therapy became an attractive
strategy for cancer treatment. In different studies, antibodies
against TfR have successfully been used to abrogate tumor
progression (30, 31). Others used toxic moieties conjugated
to Tf to selectively target cancer cells (32). After internalization
of Tf/TfR, iron dissociates from the receptor-ligand complex
and enters the cytosol forming the labile iron pool whereas the
complex gets recycled to the cell surface. Essential for the
dissociation is the acid pH in the endosomes (33), which is
maintained by V-ATPases. It is known that an inadequate
acidiﬁcation of endosomes inhibits trafﬁcking out of them
although precise mechanisms are not deﬁned yet (34). Con-
sistently, a role for V-ATPase in the internalization or proces-
sing of receptors has been shown such as for Notch (35, 36).
Our present study in breast cancer cells shows impaired TfR
internalization after archazolid treatment and connects this
with disturbed iron metabolic pathways. The generated iron
deprivation eventually induces apoptotic processes, leading to
cell death. Therefore, we suggest inhibition of V-ATPase as a
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new and effective way to target and interfere with the iron
metabolism in cancer cells.
Interestingly, there are other approaches to abrogate tumor
growth by targeting iron homeostasis. Iron chelators such as
deferoxamine and 3-AP showed antitumor effects in different
reports (37). Combination of these iron chelators with archazolid
showed synergistic cytotoxicity in breast cancer cells, which
allowed for the reduction of both chelator and inhibitor concen-
trations. Up to now there are further chelators under evaluation as
anticancer agents such as ciclopirox, tachpyridine, and deferasirox
(38).
Sufﬁcient amount of labile iron is essential for fundamental
cellular processes such as DNA synthesis and repair (39). The
enzyme that connects these processes to iron homeostasis is the
RNR. It catalyzes the formation of dNTPs by reducing the corre-
sponding ribonucleotides (14). In mammalians, class I enzymes
of RNR are present using an iron center for the catalytic reaction
(40). Not surprisingly, depleted labile iron in the cytosol of cells
affects the activity of RNR (41), thereby reducing the dNTP pool.
Consistently, our observations show decreased dCTP levels after
V-ATPase inhibition. As a consequence of reduced dNTP levels,
RNR inhibitors show an interruption of DNA synthesis and DNA
damage as reported for hydroxyurea (42, 43) and seen by arch-
azolid treatment. Various clinical cytostatics interfere with DNA
synthesis of cancer cells such as the DNA intercalating agent
doxorubicin (44). Along this line, the combination of doxorubi-
cin and archazolid was successful in reducing breast cancer
colonies synergistically, indicating a potential therapeutic rele-
vance of V-ATPase inhibition.
Besides the regulation of DNA metabolism, iron affects the
signaling through HIF1a. HIF1a is a crucial transcription factor
activated by hypoxia, upon which it inﬂuences the survival of
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tumor cells and shifts the cellular metabolism toward glycolysis
(45). For the proteasomal degradation of HIF1a via the von
Hippel–Lindau tumor suppressor, HIF1a has to be hydroxylated
byPHDs (46). This catalytic reaction is dependent on the presence
of oxygen, 2-oxogutarat, and iron (47). Consistently, archazolid-
induced iron depletion stabilizes HIF1a modifying the cellular
glucose metabolism.
DNAdamage aswell asHIF1a can evoke the stabilization of the
tumor suppressor p53 (48, 49). After activation of p53, it is able to
induce either cell-cycle arrest or apoptosis, thereby reducing
tumor progression. Cell-type origin, strength of p53-activating
stimulus, and others can inﬂuence the outcome of p53 activation
(50). p53 is widely mutated in tumors but at least 50% of all
cancers are p53wild-type tumors. Therefore, a lot of effort was put
into the development of p53 activators. Up to now, the most
advanced p53 activators are RG7112, MI-773, and DS-3032b
being in phase I clinical trials (51). Nevertheless, it has been
reported that DNA damage can trigger apoptosis independent of
p53 in p53-deﬁcient cells (52). Our work in p53 wild-type tumor
cells (MCF7 cells) showed a clear involvement of p53 in V-
ATPase–dependent cell death. Furthermore, archazolid success-
fully induced cell death in p53-mutated breast cancer cells (MDA-
MB-231) and p53-null breast cancer cells (4T1). Hence this
indicates that targeting the iron metabolism of cancer cells by
V-ATPase inhibition can hit p53 wild-type tumors as well as
mutated.Nonetheless onemight speculate that a xenograftmouse
model using a cell line expressing wild-type p53 should be more
sensitive to tumor mass reduction than our p53-null 4T1 model.
Our observations that V-ATPase inhibition generates iron dep-
rivation in the cell, thereby inﬂuencing activity of the iron-depen-
dent enzymes PHDs and RNR evokes new options for interfering
with the iron metabolism in cancer therapy. The depicted mech-
anism of action connects V-ATPase inhibition to fundamental
cellular processes such as DNA synthase and repair. We like to
point to the fact that the growth-inhibiting effects of archazolid
seen in vitro are recapitulated in a solid tumor growth model
in vivo, suggesting inhibition of V-ATPase as highly promising and
viable strategy for breast cancer treatment.
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 SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure S1 Archazolid induces apoptosis in breast cancer cells 
in vitro. (A, C, D) Cell death was assessed by flow cytometry analysis in archazolid 
(C and QVD) treated MCF7 cells after 48 h, MDA-MB-231 cells after 72 h and 4T1 
cells after 24 h. Bars are the SEM of three independent experiments performed in 
triplicates, *p<0.05 (One-way ANOVA, Newman-Keuls multiple comparison test). 
Condensed chromatin was visualized by Hoechst staining after 48 h of archazolid 
treatment in MCF7 cells and 72 h in MDA-MB-231 cells. One representative 
experiment out of three independent experiments is shown. (B) PARP-1 cleavage 
was detected by western blot upon 48 h and respectively 72 h of archazolid 
treatment in MCF7 and MDA-MB-231 cells. One representative blot out of three 
experiments is shown. 
Supplementary Figure S2: mRNA levels of ATP6V0C after knockdown. MCF7 
and MDA-MB-231 cells were transfected with siRNA-ATP6V0C and (A) mRNA was 
extracted after 72 h. qPCR analysis was assessed with the TaqMan Gene 
Expression Master Mix. Bars are the SEM of three independent experiments 
performed in triplicates. (B) ATP6V0C protein levels were detected by western blot 
after 72 h of transfection. One representative blot is shown. 
Supplementary Figure S3: Archazolid has no influence on HIF1α mRNA levels 
in MDA-MB-231 cells. MDA-MB-231 cells were stimulated with archazolid for 24 h 
and mRNA levels were assessed by SYBR® Green qPCR analysis. Bars are the 
SEM of three independent experiments performed in triplicates, p*<0.05, ns=not 
significant (One-way ANOVA, Newman-Keuls multiple comparison test). 
 Supplementary Figure S4: Archazolid induces 6PF2K3 and aldolase C mRNA 
levels. MCF7 cells were treated with archazolid for 24 h. SYBR® Green qPCR was 
performed to analyze 6PF2K3 and aldolase C mRNA levels. Bars are the SEM of 
three independent experiments performed in triplicates, p*<0.05 (One-way ANOVA, 
Newman-Keuls multiple comparison test). 
Supplementary Figure S5: Archazolid induces ferritin, transferrin and RRM2 
mRNA levels. MCF7 cells and MDA-MB-231 cells were treated with archazolid for 24 
h. SYBR® Green qPCR was performed to analyze ferritin, transferrin and RRM2 
mRNA levels. Bars are the SEM of three independent experiments performed in 
triplicates, p*<0.05 (One-way ANOVA, Newman-Keuls multiple comparison test).  
Supplementary Figure S6: Iron rescues archazolid induced reduction of 
metabolic activity in 4T1 cells. Metabolic activity of 4T1 cells after archazolid and 
iron citrate treatment was assessed by CTB assay. Bars are the SEM of three 
independent experiments performed in triplicates, p*<0.05 (One-way ANOVA, 
Newman-Keuls multiple comparison test). 
Supplementary Figure S7: Archazolid induces DSB in 4T1 cells, which is 
compensated by iron. Expression of phosphorylated H2AX was detected by 
western blot in 4T1 cells after 48 h of archazolid and iron citrate treatment. One 
representative blot out of three independent experiments is shown. 
 
 
 SUPPLEMENTARY MATERIALS AND METHODS 
Analysis of chromatin condensation  
After treatment nuclei were stained with 0.5 μg/mL Hoechst33258® (Sigma Aldrich) 
for 10 min to visualize condensed chromatin by fluorescence microscopy using a 
Zeiss Axiovert 25 (Jena, Germany). 
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ABSTRACT
Prognosis for patients suffering from T-ALL is still very poor and new strategies 
for T-ALL treatment are urgently needed. Our study shows potent anti-leukemic 
effects of the myxobacterial V-ATPase inhibitor Archazolid A. Archazolid A reduced 
growth and potently induced death of leukemic cell lines and human leukemic 
samples. By inhibiting lysosomal acidification, Archazolid A blocked activation of the 
Notch pathway, however, this was not the mechanism of V-ATPase inhibition relevant 
for cell death induction. In fact, V-ATPase inhibition by Archazolid A decreased the 
anti-apoptotic protein survivin. As underlying mode of action, this work is in line 
with recent studies from our group demonstrating that Archazolid A induced S-phase 
cell cycle arrest by interfering with the iron metabolism in leukemic cells. Our study 
provides evidence for V-ATPase inhibition as a potential new therapeutic option for 
T-ALL.
INTRODUCTION
T-cell acute lymphoblastic leukemia (T-ALL) is an 
aggressive hematopoietic malignancy. Despite advances 
in understanding of the molecular basis of T-ALL and 
intensified treatment regimens that have improved 
outcome of therapy, some patients fail conventional 
chemotherapy and T-ALL remains fatal in 20% of children 
and more than 50% of adults [1]. Along this line, new 
therapeutic approaches are urgently needed to improve 
patient prognosis.
Activating mutations in Notch1 occur in more than 
50% of T-ALLs, highlighting Notch1 as key player in 
T-ALL [2, 3]. In fact, constitutive activation of Notch1 
signaling represents the most prominent oncogenic 
pathway in T-cell transformation [1]. Therefore, targeted 
therapies to inhibit the Notch1 pathway have been 
developed. γ-secretase inhibitors (GSIs) that prevent 
Notch1 activating cleavage have been widely tested in 
preclinical models and clinical trials. However, the role 
of Notch in leukemia is still not entirely clear: on the 
one hand, it was shown that Notch signaling promotes 
cell survival and apoptosis resistance in leukemia [4, 5] 
and that Notch blockade by γ-secretase inhibition exerts 
pro-apoptotic effects in leukemia [6]. On the other hand, 
activation of Notch or of the Notch downstream target 
Hes1 inhibits leukemia development, growth and survival 
[7-9]. Furthermore, GSIs have shown only modest 
and temporary responses in leukemia therapy. These 
controversial results about Notch in leukemia demand for 
better understanding of the mechanisms that contribute 
to Notch signaling in leukemia in order to develop novel 
strategies to inhibit Notch1 signaling with alternative 
mechanism different from GSIs as potential promising 
approaches for T-ALL therapy.
Besides Notch activation at the plasma membrane 
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where ligand binding initiates y-secretase dependent 
cleavage of the Notch receptor, and subsequently NICD 
generation and translocation to the nucleus, Notch 
signaling in part depends on endocytosis. Recent reports 
showed that Notch can be activated in endosomes: in 
drosophila, Notch signaling is abolished when endosomal 
entry is blocked but is enhanced when endosomal retention 
is increased [10]. Moreover, in drosophila, acidification 
of endosomes by the V-ATPase is required for Notch 
activation [11]. 
Along this line, we hypothesized that inhibition 
of V-ATPase might be a promising strategy for T-ALL 
treatment. V-ATPase is an ATP-dependent proton pump 
that regulates pH homeostasis by translocating protons 
across membranes. The main function of V-ATPase is to 
regulate the acidification of intracellular compartments 
like lysosomes [12, 13]. V-ATPases are multisubunit 
heteromeric protein complexes with two functional 
domains: the V1 domain that is composed of eight subunits 
(A-H) mediates ATP hydrolysis and the V0 domain that 
is composed of five subunits (a, c, c’’, d, e) regulates 
proton translocation [14]. The V-ATPase is localized at 
endosomes and lysosomes and is essential for endocytotic 
processes, receptor internalization and recycling, and 
finally lysosomal degradation [13]. Therefore, V-ATPase 
is implicated in fundamental physiological processes, 
like neurotransmitter uptake, renal acidification, bone 
resorption or sperm maturation and is associated with 
pathologic conditions including osteopetrosis, renal 
tubular acidosis and disease-related processes such as 
entry of toxins and viruses [13].
Recent reports indicate important functions of 
V-ATPase in tumors. Augmented expression of V-ATPase 
in cancer cells was demonstrated to contribute to 
metastasis, survival and growth of cancer cells [15-18]. 
Localization of V-ATPase at the plasma membrane was 
associated with invasiveness of various types of cancer 
including breast, pancreatic, prostate, and melanoma 
cancer cells [14, 19-21]. V-ATPase was shown to localize 
to the plasma membrane in sarcoma cells as well and 
was elucidated as a promising target for Ewing sarcoma, 
osteosarcoma, chondrosarcoma or rhabdomyosarcoma 
[22, 23] as well as glioblastoma [24, 25]. Along this line, 
V-ATPase inhibition could represent a promising approach 
for tumor therapy. Although only few V-ATPase inhibitors 
have been described so far, their V-ATPase binding 
properties and mode of action are well-investigated. 
Amongst others, a class of natural compounds - the 
Archazolids - inhibits V-ATPase activity by binding to 
the V-ATPase V0 subunit [26-28] that is responsible for 
proton transport across the membrane [29]. Archazolids 
are macrolides that have originally been isolated from 
the myxobacterium Archangium gephyra [30], and are 
available also by chemical synthesis [31, 32]. Archazolids 
have attracted attention as highly potent V-ATPase 
inhibitors that exert promising anti-tumor effects [15-18, 
33-36]. 
Because Notch signaling activation in part depends 
on endocytosis [10, 11, 37] and V-ATPase has therefore 
been linked with the Notch pathway [35, 38], we 
hypothesized that V-ATPase inhibition might represent 
an alternative option to target leukemic cells. Therefore, 
we had a closer look on the functional effects and the 
mechanism of action, including the Notch pathway 
and cellular stress response, of the V-ATPase inhibitor 
Archazolid A in leukemic cells.
RESULTS
V-ATPase in leukemic cells
First, we analyzed the expression of the V-ATPase 
subunits in different leukemic cell lines including the 
T-ALL cell lines Jurkat and CEM, the AML cell line HL60, 
and the CML cell line K562 in comparison to non-tumor 
primary human PBMCs. Most of the V-ATPase subunits 
were comparably expressed in non-tumor PBMCs, Jurkat, 
CEM, and HL60 cells and some subunits were increased 
in K562 cells (Table 1). Immunostainings show that 
subunit c ATP6V0C which is targeted by Archazolid A, 
is localized to the lysosomal system and to the plasma 
membrane of leukemic cells (Figure 1A). As V-ATPase 
is essential for endo-lysosomal function, we analyzed 
the size of the endo-lysosomal compartment. In fact, 
the size of the endosomal compartment was increased in 
leukemic cell lines compared to non-tumor primary human 
peripheral blood mononuclear cells (PBMCs) (Figure 1B). 
This set of data suggests a potential function of V-ATPase 
in leukemia.
V-ATPase inhibition by Archazolid A impairs 
growth and induces death of leukemic cell lines
Archazolid A inhibited V-ATPase activity in 
leukemic cells as shown by staining of lysosomes with a 
pH-sensitive fluorescence dye (LysoTracker) (Figure 2A). 
Archazolid A impaired proliferation of leukemic cell lines 
Jurkat (EC50 0.56 nM) and CEM (EC50 0.51 nM) (Figure 
2B, 2C). In line, clonogenic growth of Jurkat and CEM 
cells was reduced by V-ATPase inhibition (Figure 2D, 2E). 
Moreover, as shown by Nicoletti assay (Figure 3A, 
3B) and Annexin V staining (Figure 3C), Archazolid A 
potently induced death of leukemic cell lines. In line with a 
previous report from our group [15], Archazolid A induced 
cleavage of procaspase-3, procaspase-9, and PARP, 
increased the pro-apoptotic protein BNIP3, and decreased 
the anti-apoptotic protein Bcl-XL in leukemic cells (Figure 
3D). Moreover, the pan-caspase inhibitor QVC-OPh 
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Figure 1: V-ATPase in leukemic cell lines. A. V-ATPase localization in leukemic cell lines is shown. Immunostaining of non-tumor 
primary human peripheral blood mononuclear cells (PBMCs) and leukemic cell lines (Jurkat, CEM, HL60, K562) for V-ATPase c-subunit 
(ATP6V0C, green) together with EEA1 (magenta), LAMP1 (magenta) and actin (red) is shown. Scale bar 5 µm. B. The size of the endo-
lysosomal compartment in leukemic cell lines is shown. Staining of non-tumor primary human PBMCs and leukemic cell lines (Jurkat, 
CEM, HL60, K562) for EEA1 (green) is shown. Scale bar 5 µm. The white line labels the cell border. The red lines label the endosome 
area (EEA1-positive area). Endosome area per cell was calculated and is shown in the graph. One-Way ANOVA, Tukey’s post test, ***p ≤ 
0.001 (compared to non-tumor primary PBMCs).
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Figure 2: Archazolid A inhibits growth of leukemic cell lines. A. Archazolid A inhibits lysosome acidification. Stainings of Jurkat 
cells treated with Archazolid A (Arch, 0, 0.1, 0.5, 1, 5, 10 nM, 24h) with the pH-sensitive LysoTracker are shown. n = 3. Scale bar 20 
µm. Quantification of LysoTracker staining is displayed (***p ≤ 0.001, One-Way ANOVA, Tukey, n = 3). B., C. Archazolid A inhibits the 
proliferation of leukemic cells. Inhibition rates of proliferation of Jurkat B. and CEM cells C. after treatments with Archazolid A (Arch) 
at indicated concentrations for 72h are shown. EC50 is indicated. n = 3. Scale bar 50 µm. D., E. Archazolid A inhibits clonogenic growth. 
Colony formation of Jurkat D. and CEM cells E. after treatments with Archazolid A (Arch) at indicated concentrations is shown. Scale bar 
100 µm. One-Way ANOVA, Tukey’s post test,  *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, n = 3. 
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partially rescued Archazolid A induced apoptosis (Figure 
3E). This suggests that apoptosis by Archazolid A is at 
least partially mediated via the mitochondrial pathway. 
V-ATPase inhibitor Archazolid A induces death of 
primary human leukemic cells
To analyze the potential therapeutic relevance of 
V-ATPase inhibition by Archazolid A, patient derived 
xenograft (PDX) leukemic cells were studied. Clinical 
characteristics are listed in Table 2. PDX cells enable 
repetitive in vitro testing on viable patient-derived cells, 
by passaging primary tumor cells in severely immuno-
compromised mice. These cells resemble the primary 
patient cells to a very high extent [39, 40]. In accordance 
with cell culture experiments, Archazolid A reduced 
viability (Figure 4A) and induced death of PDX human 
leukemic cell samples from different patients which was 
again shown by PI exclusion assays (Figure 4B) and 
Annexin V staining (Figure 4C). Moreover, Archazolid 
A induced cleavage of procaspase-3 in PDX samples 
(Figure 4D). This set of data demonstrates that V-ATPase 
inhibition by Archazolid A exerts anti-leukemic properties. 
V-ATPase subunit S-Jurkat CEM K562 HL60
ATP6V1A 0.70±0.07 1.41±0.11 2.83±0.47 0.70±0.05
ATP6V1B1 0.43±0.16 1.16±0.60 1.24±1.13 0.36±0.19
ATP6V1B2 0.52±0.07 0.63±0.10 0.88±0.10 0.68±0.12
ATP6V1C1 0.90±0.06 0.93±0.09 2.59±0.22 0.83±0.09
ATP6V1C2 0.79±0.21 0.48±0.11 0.75±0.15 34.28±15.71
ATP6V1D 0.96±0.01 1.19±0.14 1.87±0.05 0.24±0.01
ATP6V1E1 1.00±0.05 0.97±0.01 3.43±0.44 0.89±0.06
ATP6V1E2 0.51±0.05 0.37±0.03 0.65±0.06 0.17±0.01
ATP6V1F 1.12±0.27 1.64±0.34 5.27±0.39 1.00±0.06
ATP6V1G1 1.00±0.17 1.06±0.06 1.61±0.13 0.60±0.04
ATP6V1G2 0.12±0.03 1.00±0.14 0.11±0.03 0.06±0.01
ATP6V1G3 0.18±0.07 0.69±0.25 0.10±0.00 0.11±0.04
ATP6V1H 0.85±0.04 1.16±0.06 2.32±0.08 0.66±0.04
ATP6V0A1 0.48±0.01 1.07±0.06 10.67±0.87 0.60±0.05
ATP6V0A2 0.78±0.03 0.66±0.21 1.55±0.10 0.30±0.04
ATP6V0A3 0.01±0.00 0.11±0.01 0.37±0.24 0.68±0.07
ATP6V0A4 0.82±0.31 1.46±0.23 1.26±0.71 0.83±0.28
ATP6V0B 1.53±0.12 1.47±0.14 4.78±0.53 1.46±0.49
ATP6V0C 0.67±0.06 0.81±0.07 2.39±0.36 0.90±0.10
ATP6V0D1 0.38±0.03 0.44±0.04 1.26±0.12 0.86±0.09
ATP6V0D2 0.10±0.04 0.19±0.17 9.09±4.84 18.38±5.61
ATP6V0E1 0.34±0.08 0.72±0.16 0.84±0.03 0.62±0.04
ATP6V0E2 1.97±0.08 2.62±0.15 0.54±0.05 0.07±0.01
Table 1: mRNA expression of V-ATPase subunits of the V1 domain (A-H) and the V0 domain (a, c, c’’, d, e) is shown 
in human leukemic cell lines related to non-tumor primary human PBMCs
number Type ofLeukemia Disease stage sex age cytogenetics
ALL-169 cALL diagnosis m pediatric unknown
ALL-233 pre B ALL diagnosis m pediatric t(2;15)(p13;q15)
ALL-256 cALL unknown pediatric +8, t(9;22)(q34;q11)
ALL-363 pre B ALL diagnosis m adult BCR/ABL translocation
AML-372 AML relapse m adult Complex, including -17
AML-412 AML diagnosis f adult CN, FLT3-ITD, NPM1+
ALL-435 pre B ALL unknown pediatric t(11;19)
Table 2: Clinical characteristics of patients from which the PDX cells have been generated are shown.
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Figure 3: Archazolid A induces death of leukemic cell lines. A., B. Apoptosis rate determined by Nicoletti assay of Jurkat A. and 
CEM cells B. after treatments with Archazolid A (Arch) at indicated concentrations for 72h is shown. One-Way ANOVA, Tukey’s post test, 
***p ≤ 0.001, n = 3. C. Pictures display Annexin V staining of Jurkat cells after treatments with Archazolid A (Arch). Bar graphs show the 
apoptosis rate determined by Annexin V staining of Jurkat cells after treatments with Archazolid A (Arch) at indicated concentrations for 
24h, 48h, and 72h. One-Way ANOVA, Tukey’s post test, ***p ≤ 0.001, n = 3. D. Immunoblots of Jurkat cells treated with Archazolid A (10 
nM) for the indicated times for procaspase-3 (procasp-3), procaspase-9 (procasp-9), PARP, BNIP3, and Bcl-XL are shown. The immunoblot 
for tubulin indicates equal loading. n = 3. E. Annexin V/PI staining of cells treated with Archazolid A at indicated concentrations for 48h 
and with/without the pan-caspase inhibitor QVD-OPh (QVD) at 10 µM for 48h is shown. One-Way ANOVA, Tukey’s post test, ***p ≤ 
0.001, n = 3. 
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Because Archazolid A did not induce cell death of non-
tumor primary human PBMCs (Figure 4E) it might 
represent an option for anti-leukemic treatment.
V-ATPase inhibition by Archazolid A addresses 
Notch1 signaling in leukemic cells, but the Notch 
pathway is not responsible for Archazolid A 
induced cell death
In order to evaluate the mechanism of Archazolid A 
to induce leukemic cell death, the Notch pathway gained 
our attention. Expression of the Notch1 downstream 
target Hes1 was reduced by Archazolid A as well as by 
the y-secretase inhibitor (GSI) Dibenzazepine (DBZ) 
that served as positive control for Notch signaling 
inhibition (Figure 5A). Archazolid A reduced levels of 
Notch1 intracellular domain (NICD) and the Notch1 
downstream target c-myc (Figure 5B). As expected, DBZ 
treatment decreased NICD and c-myc as well. NICD 
expression revealed that the Notch1 pathway was active 
in PDX samples (Figure 5C). Archazolid A-mediated 
decrease of NICD (Figure 5C) proved that Archazolid A 
addressed the Notch1 pathway in PDX cells. Archazolid A 
induced cell death in these PDX samples as well (Figure 
4C and 10A), suggesting sensitivity of leukemic cells 
with Notch1 pathway activation towards Archazolid A. 
Moreover, Archazolid A increased levels of the Notch1 
whole receptor (Figure 5B). This was further analyzed by 
immunostainings which demonstrate again that Archazolid 
A abrogated NICD levels whereas the Notch1 whole 
receptor was increased (Figure 5D). Stainings for the 
lysosomal marker LAMP1 revealed large lysosomes that 
contained increased amounts of Notch1 in Archazolid A 
treated cells (Figure 5E). This suggested that Archazolid 
A inhibits Notch1 signaling in a way different from GSI: 
by capturing the Notch1 whole receptor in lysosomes and 
therefore inhibiting Notch1 cleavage and NICD generation 
at endolysosomal membranes. 
However, NICD overexpression could not rescue 
from Archazolid A-mediated cell death (Figure 6A), 
suggesting no causal relationship between the Notch1 
pathway and Archazolid A-induced leukemic cell death. 
Nevertheless, NICD overexpression induced Notch1 
downstream target gene expression (Figure 6B) and 
rescued DBZ-induced inhibition of proliferation (Figure 
6C), proving that NICD overexpression was functional. 
In order to better understand the inter-connection between 
V-ATPase and Notch1, we analyzed whether Notch 
inhibition affects levels of V-ATPase c-subunit. V-ATPase 
c-subunit expression was not affected by DBZ treatment 
(Figure 6D). This set of data indicated that Notch1 
signaling inhibition is not the major relevant downstream 
signaling of Archazolid A in leukemic cell death induction.
Inhibition of y-secretase impairs growth but does 
not induce death of leukemic cell lines
DBZ-mediated γ-secretase inhibition reduced 
proliferation of leukemic cell lines Jurkat (EC50 15.5 
µM) and CEM (EC50 12.7 µM) (Figure 7A, 7B) as well 
as clonogenic growth (Figure 7C, 7D). However, DBZ 
neither induced death of leukemic cell lines (Figure 7E-
7G), nor of human leukemic PDX samples (Figure 7H). 
This set of data suggests that the Notch1 pathway is not 
essential for the effects of Archazolid A on leukemic cell 
death.
Archazolid A decreases survivin by inducing 
cell cycle arrest and interfering with the iron 
metabolism in leukemic cells
In search for other pathways of Archazolid A 
responsible for cell death, we analyzed the anti-apoptotic 
protein survivin, a crucial regulator of cell death in 
leukemic cells [41-43]. In fact, Archazolid A decreased 
survivin protein levels (Figure 8A, 8B and Supplementary 
Figure 1) which was not due to changed survivin mRNA 
(Figure 8C). In contrast, DBZ showed no significant effect 
on survivin (Figure 8A-8C), again providing evidence 
that Archazolid A-mediated anti-leukemic effects are not 
based on Notch1 inhibition. Because survivin expression 
strongly depends on the cell cycle [41-43], subsequently, 
cell cycle analysis was performed. In fact, cells without 
Archazolid A treatment pass S-phase (8h) to reach (16h) 
and accumulate (20h, 24h) in G2-phase. In contrast, 
Archazolid A treated cells accumulate in S-phase (8h, 
16h, 20h) but do not traverse to G2-phase. This suggests 
that Archazolid A treated cells die during S-phase which is 
confirmed by cell death analysis showing that Archazolid 
A-induced S-phase arrest is in parallel with apoptosis 
induction (Figure 8D). 
In line with recent studies from our group [15, 44] 
that elucidated that interference of Archazolid with the 
iron metabolism leads to S-phase cell cycle arrest in breast 
cancer, Archazolid A stabilized Hif1α in leukemic cells 
(Figure 9A-9C) which was abrogated by simultaneous 
treatment with iron citrate (Figure 9C). In contrast, Notch 
inhibition by DBZ did not affect Hif1α (Figure 9D). As 
shown previously [44], Archazolid A-mediated cell death 
was partially rescued by iron citrate (Figure 9E). Because 
Hif1α stabilization is generally pro-proliferative, but 
also anti-proliferative and cell death inducing properties 
have been described [45-48], we analyzed the effects of 
Hif1α induction on cell death and survivin expression in 
leukemic cells. Induction of Hif1α by deferoxamine (DFO) 
induced leukemic cell death and decreased survivin, 
which was even enhanced by concomitant Archazolid A 
treatment (Figure 9F, 9G). This set of data suggests that 
interference of Archazolid A with the iron metabolism 
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Figure 4: Archazolid A induces cell death in human patient derived xenograft (PDX) samples. A. Viability of leukemic 
PDX samples with/without treatment with Archazolid A (Arch) for 72h at indicated concentrations is shown. B. PI exclusion staining of 
leukemic PDX samples with/without treatment with Archazolid A (Arch) for 48h at indicated concentrations is shown. Upper panels display 
dot plots and histograms of PDX leukemic cells from one respective patient (PDX ALL-169). Dead cells are stained by PI and are marked in 
red. Live cells without PI staining are displayed in green. Lower panels show apoptosis rate of PDX leukemic cells treated with Archazolid 
A (Arch) at indicated concentrations. C. The specific apoptosis rate determined by Annexin V/PI staining of PDX cells after treatments 
with Archazolid A (Arch) at indicated concentrations for 48h is shown. D. Immunoblots of PDX samples treated with Archazolid A (10 
nM, 48h) for procaspase-3 (procasp-3) are shown. Ponceau staining indicates equal loading. E. Archazolid A does not induce cell death in 
non-tumor primary human PBMCs. Apoptosis rate determined by Annexin V/PI staining and of non-tumor primary human PBMCs (FACS 
analysis with gating for lymphocytes) of two different donors treated with Archazolid A (Arch) at indicated concentrations for 48h is shown.
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Figure 5: Archazolid A inhibits Notch1 signaling. A. Hes1 mRNA expression of Jurkat cells treated with Archazolid A (Arch, 
10 nM, 24h) or DBZ (50 µM, 24h) is shown. Archazolid A: paired t-test, *p = 0.0341, n = 3. DBZ: paired t-test, *p = 0.0090, n = 3. B. 
Immunoblots from Jurkat cells treated with Archazolid A (Arch, 10 nM, left panel) or DBZ (10 µM, right panel) for the indicated times 
and probed with antibodies for Notch, NICD, and c-myc are shown. Immunoblots for β-tubulin indicate equal loading. Bar graphs display 
quantitative evaluations of immunoblots for Notch1, NICD, and c-myc. n = 3. C. Immunoblots from PDX cells treated with Archazolid 
A (10 nM, 24h) and probed with antibodies for NICD are shown. Ponceau staining is used as loading control. D. Immunostainings from 
Jurkat cells treated with Archazolid A (Arch, 10 nM, 24h) or DBZ (50 µM, 24h) for NICD (green, left panels) and Notch1 (green, right 
panels) are shown. n = 3. Scale bar 10 µm. Bar graphs display quantitative evaluations of NICD and Notch1 intensities. E. Immunostainings 
from Jurkat cells treated with Archazolid A (Arch, 10 nM, 24h) for LAMP1 (red) and Notch1 (green) are shown. Merged pictures indicate 
colocalization of LAMP1 and Notch1 (yellow). n = 3. Scale bar 10 µm.
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contributes to cell death in leukemic cells. 
Finally, coincident with apoptosis induction, 
survivin levels were decreased by Archazolid A treatment 
of PDX human patient samples as shown for the PDX 
samples PDX ALL-363 and PDX ALL-256 (Figure 10A, 
Figure 4C). Moreover, survivin overexpression partially 
rescued Archazolid A induced cell death in leukemic cells 
(Figure 10B). This set of data suggests decreased survivin 
as relevant mechanism of Archazolid A to induce leukemic 
cell death.
DISCUSSION
Our study demonstrates that V-ATPase inhibition 
by Archazolid A exerts anti-leukemic effects, suggesting 
V-ATPase inhibition as potential option for T-ALL 
treatment. 
During recent years, V-ATPase has emerged as 
interesting target for cancer therapy. Amongst others, 
including various studies of our group, it has been shown 
that V-ATPase is implicated in cancer cell metastasis [16, 
49], invasion [50, 51], tumor cell death [15, 52], anoikis 
resistance [17], cellular stress response [15], breast cancer 
trastuzumab resistance [34], and regulation of the secretion 
profile of cancer and cancer-associated cells [18, 53]. Only 
few reports point to a function of V-ATPase in leukemia or 
hematopoietic cells in general. In detail, it was shown that 
proton pump inhibitors induce apoptosis of human B-cells 
[54] and lysosome disruption has been associated with 
anti-leukemic effects in acute myeloid leukemia (AML) 
[55]. Moreover, V-ATPase was suggested to regulate 
Figure 6: NICD cannot rescue Archazolid A mediated induction of apoptosis. A. Apoptosis rate determined by Nicoletti assay 
(left bar graph) and by Annexin V/PI staining (right bar graph) of Jurkat cells overexpressing either empty vector or NICD after treatment 
with Archazolid A (48h) is shown. Immunoblots show NICD overexpression. n = 3. B. Increased expression of Notch downstream targets 
Hey1 (paired t-test, *p = 0.0197), Hey2 (paired t-test, p = 0.0576), NRARP (paired t-test, *p = 0.0407), Hes1 (paired t-test, p = 0.1117) after 
NICD overexpression (24h) is shown. n = 3. C. Proliferation of Jurkat cells overexpressing either empty vector or NICD after treatment 
with DBZ at indicated concentrations for 72h is shown. t-test, *p = 0.0209, n = 3. D. Expression of V-ATPase subunit c (ATP6V0C) of 
Jurkat cells treated with DBZ (50 µM, 24h) is shown. Non-significant (ns), paired t-test, p = 0.1886.
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Figure 7: y-secretase inhibition by DBZ inhibits growth but does not induce leukemic cell death. A., B. DBZ inhibits 
proliferation of leukemic cells. Inhibition rates of proliferation of Jurkat A. and CEM cells B. after treatment with DBZ for 72h at indicated 
concentrations are shown. EC50 is indicated. n = 3. Scale bar 50 µm. C., D. Colony formation of Jurkat C. and CEM cells D. after 
treatments with DBZ at indicated concentrations is shown. Scale bar 100 µm. One-Way ANOVA, Tukey, **p ≤ 0.01, ***p ≤ 0.001, n = 3. 
E., F. Apoptosis rate determined by Nicoletti assay of Jurkat E. and CEM cells F. after treatments with DBZ at indicated concentrations 
for 72h is shown. n = 3. G. Apoptosis rate determined by Annexin V/PI staining of Jurkat cells after treatments with DBZ at indicated 
concentrations for 24h, 48h, and 72h is shown. 24h and 48h: n = 2. 72h: n = 3. H. Apoptosis rate determined by PI exclusion of PDX 
leukemic cells with/without treatments with DBZ (48h) at indicated concentrations is shown.
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Figure 8: Archazolid A decreases the anti-apoptotic protein survivin and interferes with the cell cycle in leukemic 
cells. A. Archazolid A decreases the anti-apoptotic protein survivin. Immunoblots from Jurkat cells treated with Archazolid A (Arch, 10 
nM, left panel) or DBZ (50 µM, right panel) for the indicated times and probed with antibodies for survivin, XIAP, IAP1, and IAP2 are 
shown. Immunoblots for tubulin indicate equal loading. n = 3. Bar graphs display the quantitative evaluation of survivin expression. B. 
Immunostainings for survivin (green) and actin (red) after treatment with/without Archazolid A (Arch, 10 nM, 24h) and DBZ (50 µM, 24h) 
is shown. Scale bar 10 µm. C. Archazolid A (Arch) and DBZ do not interfere with survivin mRNA expression. Survivin mRNA levels from 
Jurkat cells treated with Archazolid A (1 and 10 nM) and DBZ (50 µM) for 24h are shown. Not significant (ns), Archazolid A: One-Way 
ANOVA, DBZ: paired t-test, n = 3. D. Archazolid A (Arch) induces S-phase cell cycle arrest of Jurkat cells. Cell cyle analysis and apoptosis 
measurement after aphidicolin synchronization (24h) and subsequent treatment with Archazolid A for indicated times is shown. Control 
cells (untreated, Archazolid A 0 nM) are indicated in red, Archazolid A (Arch, 10 nM) treated cells are indicated in blue. One representative 
out of three independent experiments is shown. 
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Figure 9: Archazolid A interferes with the iron metabolism in leukemic cells. A. Archazolid A increases Hif1α. Immunoblots 
show Hif1α levels of Jurkat cells with/without Archazolid A (Arch) treatment at indicated concentrations for 24h. Actin indicates 
equal loading. B. Immunostainings for Hif1α (green) and f-actin (red) after treatment with/without Archazolid A (Arch, 10 nM, 24h) is 
shown. Nuclei are labeled with Hoechst33342 (blue). Scale bar 7.5 µm. C. Archazolid A mediated Hif1α increase is abrogated by iron 
citrate. Immunoblots show Hif1α levels of Jurkat cells with/without Archazolid A (Arch) and iron citrate (FeCit) treatment at indicated 
concentrations for 24h. Actin indicates equal loading. n = 3. D. Inhibition of Notch by DBZ does not influence Hif1α. Immunoblots of 
Jurkat cells treated with DBZ and deferoxamine (DFO) at indicated concentrations for 24h for Hif1α and actin (loading control) are shown. 
E. Archazolid A mediated cell death is partially rescued by iron citrate. The graph shows cell death of Jurkat cells treated with/without 
Archazolid A (Arch) and iron citrate (FeCit) at indicated concentrations for 48 h. Mann Whitney test, **p = 0.0022, n = 3. F. DFO induces 
cell death in Jurkat cells and is enhanced by Archazolid A. Nicoletti assay of cells treated with/without Archazolid A (Arch) and DFO at 
indicated concentrations for 48 h is shown. One-Way ANOVA, Tukey’s post test, ***p ≤ 0.001, n = 3. G. Survivin is decreased by DFO 
which is enhanced by Archazolid A. Immunoblots for survivin and tubulin (loading control) from cells treated with/without DFO (100 µM) 
and Archazolid A (Arch, 10 nM) for 48h are shown; n = 3.
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Figure 10: Archazolid A-induced apoptosis in PDX is in line with decreased levels of the anti-apoptotic protein 
survivin. A. Upper panels show apoptosis rates (specific cell death) determined by PI exclusion staining of PDX leukemia samples treated 
with Archazolid A (Arch, 10 nM, 48 h). Lower panels display immunoblots from PDX cells from the same patients treated with Archazolid 
A (Arch, 10 nM, 24 h) and probed with antibodies for survivin. Immunoblots for actin indicate equal loading. B. Archazolid A mediated 
cell death is partially rescued by survivin overexpression. The graph shows early apoptosis (AnnexinV-positive and PI-negative cells) 
determined by AnnexinV/PI staining of Jurkat cells overexpressing either empty vector (ev) or survivin and treated with/without Archazolid 
A (Arch) at indicated concentrations for 48 h. One-Way ANOVA, Tukey, *p ≤ 0.05, ***p ≤ 0.001, n = 3. Immunoblots show overexpression 
of empty vector (ev) and survivin 24h after transfection; actin indicates equal loading.
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leukemic cell adhesion [56] and V-ATPase inhibition by 
Bafilomycin A reduced leukemic cell growth [35].
In search for the signaling pathway responsible 
for the anti-leukemic effects of Archazolid A-mediated 
V-ATPase inhibition, first the Notch pathway was 
analyzed as it is one of the most prominent oncogenic 
pathways in T-ALL [57]. Targeted therapies addressing 
the Notch pathway have been proposed as auspicious 
options for T-ALL treatment. Despite promising in vitro 
results and initial clinical effectiveness of GSIs that block 
Notch activatory cleavage, this benefit only in some 
studies translates into improved overall survival [58-
60]. In fact, most human T-ALL cell lines are resistant 
to GSIs that fail to induce leukemic cell death [57]. 
Therefore, to inhibit Notch signaling with a mechanism 
different from GSIs might be a promising approach. Our 
study shows that V-ATPase reduces Notch1 signaling by 
capturing the Notch whole receptor in the endolysosomal 
compartment and inhibiting its activatory cleavage. 
This is in line with reports demonstrating that impaired 
endolysosomal function by V-ATPase inhibition blocks 
γ-secretase mediated Notch activatory cleavage at the 
endolysosomal membrane [11, 35, 37, 38]. However, 
our rescue experiments revealed that leukemic cell death 
by Archazolid A was not caused by inhibition of Notch 
signaling. Moreover, although our results revealed that 
GSI treatment reduced leukemic cell growth, cell death 
was not induced. Thus, Archazolid A-mediated induction 
of leukemic cell death was not based on Notch1 pathway 
inhibition. 
Our work suggests the anti-apoptotic protein 
survivin as target addressed by Archazolid A to induce 
leukemic cell death. Survivin exerts multiple cellular 
functions: it participates in the regulation of cell 
division, apoptosis, stress response, migration, and 
metastasis. Whereas it is nearly absent in normal tissues, 
it is overexpressed in most human tumors, including 
hematopoietic malignancies [42, 43, 61-63]. Survivin 
expression has been associated with leukemia progression 
and poor clinical outcome [64-66]. In consequence, 
survivin is addressed in cancer therapy by molecular 
antagonists like antisense oligonucleotides, siRNA, or 
hammerhead ribozymes, as well as small molecules or 
cancer immunotherapeutics [67]. Inhibition of survivin 
has shown clinical benefits and chemosensitizing effects 
in leukemia [42, 43, 68-70]. By describing potent anti-
leukemic effects of Archazolid A, our study probably 
expands the class of small molecule survivin antagonists.
Survivin expression strongly depends on the cell 
cycle, i.e. survivin is upregulated and stabilized during 
G2-phase [41]. Besides regulation at the transcriptional 
level, changes in protein stability essentially contribute 
to survivin expression during the cell cycle: proteasome-
dependent destruction of survivin has been shown 
in interphase cells whereas at metaphase, mitotic 
phosphorylation of survivin by Cdk1 has been associated 
with increased protein stability [71]. In fact, in line with 
recent studies from our group addressing V-ATPase 
in cancer [15, 44], our results presented here suggest 
that Archazolid decreased survivin at the protein level 
by inducing S-phase cell cycle arrest in leukemic cells 
which probably was due to its interference with the iron 
metabolism. 
In line with previous studies from our group 
showing that Archazolid B led to cellular stress response 
and induction of Hif1α [15, 44], our present study suggests 
that the induction of Hif1α contributes to Archazolid A 
induced leukemic cell death. Although the stabilization 
of Hif1α during hypoxia is generally pro-proliferative 
as stabilization of Hif1α influences the survival of tumor 
cells, Hif1α has also tumor-inhibiting properties. In 
detail, Hif1α overexpression inhibits cell proliferation by 
expressing cell cycle inhibitors like p53, p21, and p27 and 
promotes apoptosis by inducing pro-apoptotic molecules 
such as p53, Nip3, and Noxa [45-48].
A recent study from our group demonstrated that 
inhibition of V-ATPase by Archazolid B led to iron 
depletion by disruption of transferrin receptor recycling 
which subsequently reduced ribonucleotide reductase 
(RNR) activity, induced S-phase cell cycle arrest and 
finally caused cell death [44]. Interestingly, iron overload 
due to inefficient erythropoiesis or blood transfusion 
represents a major problem in patients suffering from 
myelodysplastic syndromes (MDS), clonal disorders 
with ineffective hematopoiesis and an increased risk of 
transformation into acute myeloid leukemia. Iron overload 
is associated with osteopenia and osteoporosis in these 
patients [72, 73]. In consequence, V-ATPase inhibition in 
hematopoietic diseases might be an interesting object for 
further studies.
To conclude, our study provides evidence for 
V-ATPase inhibition as new alternative strategy and 
Archazolid A as interesting new compound for T-ALL 
therapy.
MATERIALS AND METHODS
Cells
Cell lines: Human leukemia Jurkat T cells (J16, 
S-Jurkat) were kindly provided by P.H. Krammer and 
H. Walczak, Heidelberg, Germany. S-Jurkat cells were 
cultured in RPMI 1640 (PAN Biotech, Aidenbach, 
Germany) containing 10% FCS (PAA Laboratories, 
Cölbe, Germany) and 1% pyruvate (Merck, Darmstadt, 
Germany). CCRF-CEM cells were kindly provided by Dr. 
Joachim Arend (Mainz, Germany) and cultured in RPMI 
1640 containing 10% FCS.
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Reagents
The γ-secretase inhibitor DBZ was purchased from 
Merck Millipore. The pan-caspase inhibitor QVD-OPh 
(551476) was purchased from Calbiochem. Deferoxamine 
(DFO) was purchased from Sigma.
Patient-derived xenograft (PDX) leukemic cells
The xenograft mouse model, the transplantation of 
patient’s primary tumor cells, and the cell amplification 
have been described previously [39, 40]. In detail, 
primary leukemic cells were obtained from diagnostic 
bone marrow aspiration or peripheral blood sampling 
before onset of treatment. Xenografts were established 
by injecting 107 fresh or frozen/thawed primary leukemic 
cells into NSG mice (NOD SCID gamma mice, i.e. mice 
with dysfunctional gamma chain of the IL-2R receptor) 
by tail vein injection. Development of leukemia was 
monitored by repetitive blood sampling in mice and by 
determining human leukemic cells in flow cytometry 
upon staining of murine CD45 and human CD38. At clear 
leukemic engraftment or by latest after 25 weeks, mice 
were sacrificed and human patient-derived xenograft 
(PDX) leukemic cells were isolated either from bone 
marrow or from spleens of mice using Ficoll purification. 
Phenotypic markers and genetic aberrations in PDX cells 
compared to primary leukemic tumor cells remained 
mainly stable as shown before [25]. For stimulation and 
during experiments, cells were maintained in RPMI 1640 
medium containing 20% FCS and 1% glutamine. Freshly 
isolated PDX leukemic cells were stimulated as indicated 
in vitro.
Primary non-tumor human peripheral blood 
mononuclear cells (PBMCs)
Isolation of primary non-tumor human PBMCs was 
performed using the “Ficoll-Paque PLUS” kit from GE 
Healthcare according to the manufacturer’s instructions. 
Briefly, EDTA (1.5mg/ml) blood (2 ml) was mixed with 
balanced salt solution (2 ml), added on top of Ficoll-Paque 
PLUS (3ml) in a 15ml centrifuge tube, and centrifuged 
(400×g, 40min, RT). Afterwards, PBMCs were carefully 
withdrawn from the interface between the upper plasma 
layer and the lower Ficoll-Paque PLUS layer, washed 
twice by 3 volumes of balanced salt solution, centifuged 
(100×g, 10 min, RT) and resuspended in culture medium 
(RPMI 1640+20%FCS+1%Glutamine). PBMCs were 
directly used for the respective assays.
For FACS analysis, gating of lymphocytes was 
performed and only these cells were included in the 
evaluation.
Tansfection of cells
Cell transfection was performed by using the 
Amaxxa system with the cell line nucleofector kit V 
(Lonza, VCA-1003) according to the manufacturer’s 
instructions. 1×106 cells were electroporated (program 
X-001). NICD plasmid was from addgene (20183). 
Survivin plasmid was from Sino Biologicals (pCMV3-
BIRC5-myc, HG10356-CM G09AU4M62). For respective 
assays, cells were used 24h (NICD) or 48h (survivin) after 
transfection.
Proliferation
CellTiter-Blue® assay was performed according 
manufacturer’s instructions. Briefly, cells were seeded 
(96 well plates, 3×103 cells/well) for 24 h, treated with 
Archazolid A or DBZ at indicated concentrations and 
incubated for 70 h. CTB solution (20μl) was added and 
cells were incubated for 2h. Fluorescence was measured 
with a Tecan reader (Maennedorf, Austria). 
PDX viability
PDX leukemic cells were seeded (96 well 
plates, 1x105 cells/well) and the cells were treated with 
Archazolid A at indicated concentrations for 72h. Cell 
Titer Blue assay was performed according manufacturer’s 
instructions as described before at “proliferation”. For 
calculating viability, the value from the time of plating 
was subtracted.
Apoptosis and cell cycle
Apoptosis and cell cycle analysis were performed 
according to the Nicoletti method [74]. In brief, cells were 
seeded (24 well plates, 0.5×104 cells/well for 48 h, 2.5×104 
cells/well for 72 h) and treated with Archazolid A or DBZ 
at indicated concentrations. For DNA staining, cells were 
permeabilized and stained by resuspension in hypotonic 
fluorochrome solution (HFS) containing propidium 
iodide (PI, 50 µg/ml) and incubated at 4°C overnight. 
Subsequently, flow cytometry was performed on a 
FACSCalibur (Becton Dickinson, Heidelberg, Germany). 
The sub-G1 peak accounts for apoptotic cells and was 
determined according to Nicoletti [74]. Cell cycle was 
analyzed by using FlowJo 7.6 (Tree Star Unc., Ashland, 
USA).
PI exclusion
Cells were seeded (96 well plates, 1×105 cells/
well and treated with Archazolid A or DBZ at indicated 
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concentrations. Subsequently, cells were incubated with 
PI (5 μg/ml, 5 min) that was added to the cell suspension 
before analysis by flow cytometry. Subsequently, flow 
cytometry was performed on a FACSCalibur (Becton 
Dickinson, Heidelberg, Germany) using the Fl-2 laser.
As cells were not permeabilized, PI staining was 
exclusive for dead cells, whereas viable cells were not 
stained by PI. For quantification, PI positive dead cells 
can be seen in dot plots at the left and in histograms at the 
right and are shown in red; PI negative viable cells can be 
seen in dot plots at the right and in histograms at the left 
and are shown in green (Figure 4A).
Annexin V/PI staining
Annexin V/PI staining was performed by using the 
Annexin V-FITC Apoptosis Detection Kit (eBioscience 
Dx, BMS500FI/300CE) according to the manufacturer’s 
protocol. Briefly, cells were treated as indicated, collected, 
centrifuged (600g, 4 oC, 10min), washed with PBS, 
centrifuged again (600g, 4 oC, 10min) and resuspended 
in binding buffer. 5μl AnnexinV-FITC were added to 
195μl of cell suspension, cells were mixed and incubated 
at RT for 10 min (cover from light), centrifuged (600g, 
4 oC, 10min), washed with 200μl Binding Buffer and 
resuspended in Binding Buffer. 10μl PI (20μg/ml) was 
added to 190 µl of cell suspension and FACS analysis was 
performed using Fl-2 and Fl-3 lasers. AnnexinV positive 
cells have been considered as apoptotic. AnnexinV 
positive and PI negative cells have been considered as 
early apoptotic.
For primary PDX leukemic cells, the specific 
apoptosis was calculated according to the following 
formula: % specific apoptosis = 100 × (% total apoptosis 
of treated cells - % total apoptosis of untreated cells) / 
(100 - % total apoptosis untreated cells) [75]. 
For primary non-tumor human PBMCs, gating of 
lymphocytes was performed and only these cells were 
included in the evaluation.
Colony formation
Cells were seeded (6 well plates, 5×105 cells/ 
well) and treated with Archazolid A or DBZ at indicated 
concentrations for 24h. Cells were freshly plated (96 
well plates, 5×103 cells/well) in RPMI 1640 Medium 
containing 40% FCS, 0.52% Methylcellulose, and 1% 
Sodium Pyruvate and incubated for 11 d. Images from 
each well were taken with a Zeiss 510 Meta Confocal 
Microscope. Colonies were counted by using Image J with 
the cell counter plugin.
Immunoblotting
Immunoblotting was performed as described 
[76]. The following primary antibodies were used: actin 
(MAB1501 Millipore), BCL-XL (2762 Cell Signaling), 
BNIP3 (ab10433 Abcam), Caspase 3 (sc-7148 Santa 
Cruz), Caspase 9 (9506 Cell Signaling), Hif1α (610958 
BD), IAP-1 (4952 Cell Signaling), IAP-2 (3130 Cell 
Signaling), NICD (4147 Cell Signaling), Notch1 (4380 
Cell Signaling), c-Myc (sc-788 Santa Cruz), survivin 
(2803 Cell Signaling), β-tubulin (2164 Cell Signaling), 
XIAP (610717 BD).
RT-PCR
mRNA was isolated using the Qiagen RNeasy Mini 
Kit. For reverse transcription the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) was 
used. RT-PCR was performed with the 7300 Real Time 
PCR System. 
For RT-PCR of Notch downstream targets, the 
following Taqman gene expression assays were used: Hes1 
Hs00172878, HEY1 Hs00232618, HEY2 Hs00232622, 
NRARP Hs01104102 (Life Technologies Corporation, 
Carlsbad, CA, USA). GAPDH was used as housekeeper.
For RT-PCR for V-ATPase subunits, SYBR® Green 
PCR Master Mix (4309155, Life Technologies) was used. 
A list with the primer sequences for all V-ATPase subunits 
is included in Supplementary Table 1.
Confocal microscopy
For Immunostaining with antibodies, cells were 
treated as indicated, collected, resuspended and seeded 
on chrome alum-gelatin (0.05% CrK(SO4)2·12H2O, 0.4% 
gelatine in H2O) coated coverslips (30 min). Cells were 
fixed (4% PFA, 10mins), permablized (0.2% Triton X 
100 in PBS, 5min), blocked (0.2% BSA in PBS, 1 h), 
incubated with primary antibodies (0.2% BSA in PBS, 
1h) and subsequently secondary antibodies (0.2% BSA in 
PBS, 1h) and mounted. The following primary antibodies 
were used: EEA1 (sc-6415, Santa Cruz), LAMP1 (H4A3, 
Developmental Studies Hybridoma Bank), NICD (4147 
Cell Signalling), Notch1 (4308, Cell Signaling). Alexa 
Fluor conjugated secondary antibodies (Molecular Probes) 
were used. 
For LysoTracker experiment, cells were treated 
as indicated, collected, and stained with LysoTracker 
(Molecular Probes) for 45min. After Hoechst33342 
staining (5 µg/ml, 5min), confocal microscopy was 
performed with a Zeiss LSM 510 META confocal 
microscope.
For the evaluation of the size of the endolysosomal 
compartment, EEA1 staining was performed. The size 
Oncotarget18www.impactjournals.com/oncotarget
of the endolysosomal compartment was analyzed by 
calculating the EEA1-positive area per cell by using 
ImageJ. Approximately 20 cells per cell line were 
randomly selected for the evaluation.
The quantification of the intensities of Notch1 and 
NICD staining was performed by using Image J. The total 
intensity of the whole image was divided by the number 
of cells. Cells on the border of the images were excluded.
Statistic evaluation
All experiments were performed at least 3 times in 
duplicates/triplicates. Results are expressed as mean value 
± SEM. One-way ANOVA/Tukey and individual t-tests 
were conducted using GraphPad Prism (version 5.04, 
GraphPad Software, Inc.). P values less than 0.05 were 
considered as significant.
ACKNOWLEDGMENTS
The authors thank Kerstin Loske and Jana Peliskova 
for their help with the experiments.
FUNDING
S.Z. was supported by the Chinese Scholarship 
Council (CSC). A.M.V. received financial support by the 
German Research Foundation (DFG, FOR 1406, Vo 376-
14/15)
CONFLICTS OF INTEREST
The authors declare no conflict of interest.
REFERENCES
1. Van Vlierberghe P and Ferrando A. The molecular basis of 
T cell acute lymphoblastic leukemia. J Clin Invest. 2012; 
122:3398-3406.
2. Koch U and Radtke F. Notch in T-ALL: new players in a 
complex disease. Trends Immunol. 2011; 32:434-442.
3. Pancewicz J and Nicot C. Current views on the role of 
Notch signaling and the pathogenesis of human leukemia. 
BMC Cancer. 2011; 11:502.
4. De Falco F, Sabatini R, Del Papa B, Falzetti F, Di Ianni 
M, Sportoletti P, Baldoni S, Screpanti I, Marconi P and 
Rosati E. Notch signaling sustains the expression of Mcl-1 
and the activity of eIF4E to promote cell survival in CLL. 
Oncotarget. 2015; 6:16559-16572.
5. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni 
M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I and 
Marconi P. Constitutively activated Notch signaling is 
involved in survival and apoptosis resistance of B-CLL 
cells. Blood. 2009; 113:856-865.
6. Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di 
Ianni M, Cavalli L, Fettucciari K, Bartoli A, Screpanti I and 
Marconi P. gamma-Secretase inhibitor I induces apoptosis 
in chronic lymphocytic leukemia cells by proteasome 
inhibition, endoplasmic reticulum stress increase and notch 
down-regulation. Int J Cancer. 2013; 132:1940-1953.
7. Tian C, Yu Y, Jia Y, Zhu L and Zhang Y. HES1 activation 
suppresses proliferation of leukemia cells in acute myeloid 
leukemia. Annals of hematology. 2015; 94:1477-83.
8. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, 
Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau 
SM, Melnick AM, Figueroa ME and Zweidler-McKay PA. 
Notch activation inhibits AML growth and survival: a 
potential therapeutic approach. J Exp Med. 2013; 210:321-
337.
9. Kato T, Sakata-Yanagimoto M, Nishikii H, Ueno M, 
Miyake Y, Yokoyama Y, Asabe Y, Kamada Y, Muto H, 
Obara N, Suzukawa K, Hasegawa Y, Kitabayashi I, Uchida 
K, Hirao A, Yagita H, et al. Hes1 suppresses acute myeloid 
leukemia development through FLT3 repression. Leukemia. 
2015; 29:576-585.
10. Vaccari T, Lu H, Kanwar R, Fortini ME and Bilder D. 
Endosomal entry regulates Notch receptor activation in 
Drosophila melanogaster. J Cell Biol. 2008; 180:755-762.
11. Vaccari T, Duchi S, Cortese K, Tacchetti C and Bilder 
D. The vacuolar ATPase is required for physiological as 
well as pathological activation of the Notch receptor. 
Development. 2010; 137:1825-1832.
12. Nishi T and Forgac M. The vacuolar (H+)-ATPases—
nature’s most versatile proton pumps. Nat Rev Mol Cell 
Biol. 2002; 3:94-103.
13. Forgac M. Vacuolar ATPases: rotary proton pumps in 
physiology and pathophysiology. Nat Rev Mol Cell Biol. 
2007; 8:917-929.
14. Cotter K, Capecci J, Sennoune S, Huss M, Maier M, 
Martinez-Zaguilan R and Forgac M. Activity of plasma 
membrane V-ATPases is critical for the invasion of MDA-
MB231 breast cancer cells. J Biol Chem. 2015; 290:3680-
3692.
15. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, 
Zischka H, Wanner G, Efferth T, Trauner D and Vollmar 
AM. Mode of cell death induction by pharmacological 
vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem. 
2013; 288:1385-1396.
16. Wiedmann RM, von Schwarzenberg K, Palamidessi A, 
Schreiner L, Kubisch R, Liebl J, Schempp C, Trauner 
D, Vereb G, Zahler S, Wagner E, Muller R, Scita G and 
Vollmar AM. The V-ATPase-inhibitor archazolid abrogates 
tumor metastasis via inhibition of endocytic activation of 
the Rho-GTPase Rac1. Cancer Res. 2012; 72:5976-5987.
17. Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch 
R, Muller R, Wagner E and Vollmar AM. V-ATPase 
inhibition regulates anoikis resistance and metastasis of 
cancer cells. Mol Cancer Ther. 2014; 13:926-937.
Oncotarget19www.impactjournals.com/oncotarget
18. Kubisch R, Frohlich T, Arnold GJ, Schreiner L, von 
Schwarzenberg K, Roidl A, Vollmar AM and Wagner E. 
V-ATPase inhibition by archazolid leads to lysosomal 
dysfunction resulting in impaired cathepsin B activation in 
vivo. Int J Cancer. 2014; 134:2478-2488.
19. Chung C, Mader CC, Schmitz JC, Atladottir J, Fitchev P, 
Cornwell ML, Koleske AJ, Crawford SE and Gorelick F. 
The vacuolar-ATPase modulates matrix metalloproteinase 
isoforms in human pancreatic cancer. Laboratory 
investigation; a journal of technical methods and pathology. 
2011; 91:732-743.
20. Nishisho T, Hata K, Nakanishi M, Morita Y, Sun-Wada 
GH, Wada Y, Yasui N and Yoneda T. The a3 isoform 
vacuolar type H(+)-ATPase promotes distant metastasis 
in the mouse B16 melanoma cells. Mol Cancer Res. 2011; 
9:845-855.
21. Michel V, Licon-Munoz Y, Trujillo K, Bisoffi M and Parra 
KJ. Inhibitors of vacuolar ATPase proton pumps inhibit 
human prostate cancer cell invasion and prostate-specific 
antigen expression and secretion. Int J Cancer. 2013; 
132:E1-10.
22. Avnet S, Di Pompo G, Lemma S, Salerno M, Perut F, 
Bonuccelli G, Granchi D, Zini N and Baldini N. V-ATPase 
is a candidate therapeutic target for Ewing sarcoma. 
Biochimica et biophysica acta. 2013; 1832:1105-1116.
23. Perut F, Avnet S, Fotia C, Baglio SR, Salerno M, Hosogi 
S, Kusuzaki K and Baldini N. V-ATPase as an effective 
therapeutic target for sarcomas. Exp Cell Res. 2014; 
320:21-32.
24. Di Cristofori A, Ferrero S, Bertolini I, Gaudioso G, Russo 
MV, Berno V, Vanini M, Locatelli M, Zavanone M, 
Rampini P, Vaccari T, Caroli M and Vaira V. The vacuolar 
H+ ATPase is a novel therapeutic target for glioblastoma. 
Oncotarget. 2015; 6:17514-31.
25. Hamm R, Zeino M, Frewert S and Efferth T. Up-regulation 
of cholesterol associated genes as novel resistance 
mechanism in glioblastoma cells in response to archazolid 
B. Toxicology and applied pharmacology. 2014; 281:78-86.
26. Huss M and Wieczorek H. Inhibitors of V-ATPases: old and 
new players. J Exp Biol. 2009; 212(Pt 3):341-346.
27. Bockelmann S, Menche D, Rudolph S, Bender T, Grond S, 
von Zezschwitz P, Muench SP, Wieczorek H and Huss M. 
Archazolid A binds to the equatorial region of the c-ring of 
the vacuolar H+-ATPase. J Biol Chem. 2010; 285:38304-
38314.
28. Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, 
Ingenhorst G, Zeeck A and Wieczorek H. Archazolid and 
apicularen: novel specific V-ATPase inhibitors. BMC 
biochemistry. 2005; 6:13.
29. Huss M, Vitavska O, Albertmelcher A, Bockelmann 
S, Nardmann C, Tabke K, Tiburcy F and Wieczorek 
H. Vacuolar H(+)-ATPases: intra- and intermolecular 
interactions. Eur J Cell Biol. 2011; 90:688-695.
30. Sasse F, Steinmetz H, Hofle G and Reichenbach 
H. Archazolids, new cytotoxic macrolactones from 
Archangium gephyra (Myxobacteria). Production, isolation, 
physico-chemical and biological properties. The Journal of 
antibiotics. 2003; 56:520-525.
31. Menche D, Hassfeld J, Li J and Rudolph S. Total synthesis 
of archazolid A. Journal of the American Chemical Society. 
2007; 129:6100-6101.
32. Roethle PA, Chen IT and Trauner D. Total synthesis of 
(-)-archazolid B. Journal of the American Chemical Society. 
2007; 129:8960-8961.
33. Rath S, Liebl J, Furst R, Vollmar AM and Zahler S. 
Regulation of endothelial signaling and migration by 
v-ATPase. Angiogenesis. 2014; 17:587-601.
34. von Schwarzenberg K, Lajtos T, Simon L, Muller R, Vereb 
G and Vollmar AM. V-ATPase inhibition overcomes 
trastuzumab resistance in breast cancer. Mol Oncol. 2014; 
8:9-19.
35. Kobia F, Duchi S, Deflorian G and Vaccari T. 
Pharmacologic inhibition of vacuolar H+ ATPase reduces 
physiologic and oncogenic Notch signaling. Mol Oncol. 
2014; 8:207-220.
36. Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, 
Rey JM and Garcia-Garcia A. V-ATPase inhibitors and 
implication in cancer treatment. Cancer Treat Rev. 2009; 
35:707-713.
37. Yan Y, Denef N and Schupbach T. The vacuolar proton 
pump, V-ATPase, is required for notch signaling and 
endosomal trafficking in Drosophila. Dev Cell. 2009; 
17:387-402.
38. Valapala M, Hose S, Gongora C, Dong L, Wawrousek EF, 
Samuel Zigler J, Jr. and Sinha D. Impaired endolysosomal 
function disrupts Notch signalling in optic nerve astrocytes. 
Nat Commun. 2013; 4:1629.
39. Terziyska N, Castro Alves C, Groiss V, Schneider K, 
Farkasova K, Ogris M, Wagner E, Ehrhardt H, Brentjens 
RJ, zur Stadt U, Horstmann M, Quintanilla-Martinez L 
and Jeremias I. In vivo imaging enables high resolution 
preclinical trials on patients‘ leukemia cells growing in 
mice. PLoS One. 2012; 7:e52798.
40. Vick B, Rothenberg M, Sandhofer N, Carlet M, 
Finkenzeller C, Krupka C, Grunert M, Trumpp A, 
Corbacioglu S, Ebinger M, Andre MC, Hiddemann W, 
Schneider S, Subklewe M, Metzeler KH, Spiekermann K, et 
al. An advanced preclinical mouse model for acute myeloid 
leukemia using patients‘ cells of various genetic subgroups 
and in vivo bioluminescence imaging. PLoS One. 2015; 
10:e0120925.
41. Altieri DC. Survivin, cancer networks and pathway-directed 
drug discovery. Nat Rev Cancer. 2008; 8:61-70.
42. Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm 
L, Huantes S, Loh M, Conway EM, Kang ES, Hoe Koo 
H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan 
G, Crispino J, et al. Targeting survivin overcomes drug 
resistance in acute lymphoblastic leukemia. Blood. 2011; 
Oncotarget20www.impactjournals.com/oncotarget
118:2191-2199.
43. Purroy N, Abrisqueta P, Carabia J, Carpio C, Calpe E, 
Palacio C, Castellvi J, Crespo M and Bosch F. Targeting 
the proliferative and chemoresistant compartment in chronic 
lymphocytic leukemia by inhibiting survivin protein. 
Leukemia. 2014; 28(10):1993-2004.
44. Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, 
Kubisch-Dohmen R, Liebl J, Trauner D, Menche D and 
Vollmar AM. Vacuolar-ATPase Inhibition Blocks Iron 
Metabolism to Mediate Therapeutic Effects in Breast 
Cancer. Cancer Res. 2015; 75:2863-2874.
45. Greijer AE and van der Wall E. The role of hypoxia 
inducible factor 1 (HIF-1) in hypoxia induced apoptosis. 
Journal of clinical pathology. 2004; 57:1009-1014.
46. Koshiji M and Huang LE. Dynamic balancing of the dual 
nature of HIF-1alpha for cell survival. Cell Cycle. 2004; 
3:853-854.
47. Sermeus A and Michiels C. Reciprocal influence of the 
p53 and the hypoxic pathways. Cell death & disease. 2011; 
2:e164.
48. Fridman JS and Lowe SW. Control of apoptosis by p53. 
Oncogene. 2003; 22:9030-9040.
49. Sennoune SR, Bermudez LE, Lees JC, Hirsch J, Filleur 
S and Martinez-Zaguilan R. Vacuolar H+-ATPase is 
down-regulated by the angiogenesis-inhibitory pigment 
epithelium-derived factor in metastatic prostate cancer cells. 
Cell Mol Biol (Noisy-le-grand). 2014; 60:45-52.
50. Hinton A, Sennoune SR, Bond S, Fang M, Reuveni M, 
Sahagian GG, Jay D, Martinez-Zaguilan R and Forgac 
M. Function of a subunit isoforms of the V-ATPase in pH 
homeostasis and in vitro invasion of MDA-MB231 human 
breast cancer cells. J Biol Chem. 2009; 284:16400-16408.
51. Fan SH, Wang YY, Lu J, Zheng YL, Wu DM, Zhang ZF, 
Shan Q, Hu B, Li MQ and Cheng W. CERS2 Suppresses 
Tumor Cell Invasion and Is Associated with Decreased 
V-ATPase and MMP-2/MMP-9 activities in Breast Cancer. 
J Cell Biochem. 2015; 116:502-13.
52. Graham RM, Thompson JW and Webster KA. Inhibition 
of the vacuolar ATPase induces Bnip3-dependent death of 
cancer cells and a reduction in tumor burden and metastasis. 
Oncotarget. 2014; 5:1162-1173.
53. Scherer O, Steinmetz H, Kaether C, Weinigel C, Barz D, 
Kleinert H, Menche D, Muller R, Pergola C and Werz 
O. Targeting V-ATPase in primary human monocytes 
by archazolid potently represses the classical secretion 
of cytokines due to accumulation at the endoplasmic 
reticulum. Biochem Pharmacol. 2014; 91:490-500.
54. De Milito A, Iessi E, Logozzi M, Lozupone F, Spada M, 
Marino ML, Federici C, Perdicchio M, Matarrese P, Lugini 
L, Nilsson A and Fais S. Proton pump inhibitors induce 
apoptosis of human B-cell tumors through a caspase-
independent mechanism involving reactive oxygen species. 
Cancer Res. 2007; 67:5408-5417.
55. Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, 
Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne 
A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, 
Spagnuolo PA, et al. Lysosomal disruption preferentially 
targets acute myeloid leukemia cells and progenitors. J Clin 
Invest. 2013; 123:315-328.
56. Funayama K, Murai F, Shimane M, Nomura H and Asano 
S. Adhesion-induced drug resistance in leukemia stem cells. 
Pharmacology. 2010; 86:79-84.
57. O’Neil J, Grim J, Strack P, Rao S, Tibbitts D, Winter C, 
Hardwick J, Welcker M, Meijerink JP, Pieters R, Draetta 
G, Sears R, Clurman BE and Look AT. FBW7 mutations 
in leukemic cells mediate NOTCH pathway activation and 
resistance to gamma-secretase inhibitors. J Exp Med. 2007; 
204:1813-1824.
58. Breit S, Stanulla M, Flohr T, Schrappe M, Ludwig WD, 
Tolle G, Happich M, Muckenthaler MU and Kulozik AE. 
Activating NOTCH1 mutations predict favorable early 
treatment response and long-term outcome in childhood 
precursor T-cell lymphoblastic leukemia. Blood. 2006; 
108:1151-1157.
59. van Grotel M, Meijerink JP, Beverloo HB, Langerak 
AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den 
Boer ML, Horstmann M, Kamps WA, Veerman AJ, van 
Wering ER, van Noesel MM and Pieters R. The outcome 
of molecular-cytogenetic subgroups in pediatric T-cell 
acute lymphoblastic leukemia: a retrospective study of 
patients treated according to DCOG or COALL protocols. 
Haematologica. 2006; 91:1212-1221.
60. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, 
Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta 
E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA 
and Linch DC. Prognostic implications of NOTCH1 and 
FBXW7 mutations in adults with T-cell acute lymphoblastic 
leukemia treated on the MRC UKALLXII/ECOG E2993 
protocol. J Clin Oncol. 2009; 27:4352-4356.
61. Carter BZ, Milella M, Altieri DC and Andreeff M. 
Cytokine-regulated expression of survivin in myeloid 
leukemia. Blood. 2001; 97:2784-2790.
62. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes 
KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, 
Mills GB, Andreeff M and Kornblau SM. Survivin is highly 
expressed in CD34(+)38(-) leukemic stem/progenitor cells 
and predicts poor clinical outcomes in AML. Blood. 2012; 
120:173-180.
63. Fukuda S, Hoggatt J, Singh P, Abe M, Speth JM, Hu P, 
Conway EM, Nucifora G, Yamaguchi S and Pelus LM. 
Survivin modulates genes with divergent molecular 
functions and regulates proliferation of hematopoietic stem 
cells through Evi-1. Leukemia. 2015; 29:433-40.
64. Smolewski P and Robak T. Inhibitors of apoptosis proteins 
(IAPs) as potential molecular targets for therapy of 
hematological malignancies. Curr Mol Med. 2011; 11:633-
649.
65. Glodkowska-Mrowka E, Solarska I, Mrowka P, Bajorek K, 
Niesiobedzka-Krezel J, Seferynska I, Borg K and Stoklosa 
Oncotarget21www.impactjournals.com/oncotarget
T. Differential expression of BIRC family genes in chronic 
myeloid leukaemia—BIRC3 and BIRC8 as potential new 
candidates to identify disease progression. Br J Haematol. 
2014; 164:740-742.
66. Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema 
NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS and 
Meshinchi S. BIRC5 (survivin) splice variant expression 
correlates with refractory disease and poor outcome 
in pediatric acute myeloid leukemia: a report from the 
Children’s Oncology Group. Pediatr Blood Cancer. 2014; 
61:647-652.
67. Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013; 
332:225-228.
68. Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, 
Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, 
Cassar J, Malvar J, Buchbinder A and Carroll WL. A phase I 
study of EZN-3042, a novel survivin messenger ribonucleic 
acid (mRNA) antagonist, administered in combination with 
chemotherapy in children with relapsed acute lymphoblastic 
leukemia (ALL): a report from the therapeutic advances in 
childhood leukemia and lymphoma (TACL) consortium. J 
Pediatr Hematol Oncol. 2014; 36:458-463.
69. Chen J, Pise-Masison CA, Shih JH, Morris JC, Janik JE, 
Conlon KC, Keating A and Waldmann TA. Markedly 
additive antitumor activity with the combination of a 
selective survivin suppressant YM155 and alemtuzumab in 
adult T-cell leukemia. Blood. 2013; 121:2029-2037.
70. Andersen MH, Svane IM, Becker JC and Straten PT. The 
universal character of the tumor-associated antigen survivin. 
Clin Cancer Res. 2007; 13:5991-5994.
71. Altieri DC. Validating survivin as a cancer therapeutic 
target. Nat Rev Cancer. 2003; 3:46-54.
72. Bulycheva E, Rauner M, Medyouf H, Theurl I, Bornhauser 
M, Hofbauer LC and Platzbecker U. Myelodysplasia 
is in the niche-novel concepts and emerging therapies. 
Leukemia. 2015; 29:259-68.
73. Breccia M and Alimena G. Efficacy and safety of 
deferasirox in myelodysplastic syndromes. Ann Hematol. 
2013; 92:863-870.
74. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and 
Riccardi C. A rapid and simple method for measuring 
thymocyte apoptosis by propidium iodide staining and flow 
cytometry. J Immunol Methods. 1991; 139:271-279.
75. Muscolini M, Cianfrocca R, Sajeva A, Mozzetti S, 
Ferrandina G, Costanzo A and Tuosto L. Trichostatin A 
up-regulates p73 and induces Bax-dependent apoptosis in 
cisplatin-resistant ovarian cancer cells. Mol Cancer Ther. 
2008; 7:1410-1419.
76. Liebl J, Zhang S, Moser M, Agalarov Y, Demir CS, Hager 
B, Bibb JA, Adams RH, Kiefer F, Miura N, Petrova TV, 
Vollmar AM and Zahler S. Cdk5 controls lymphatic vessel 
development and function by phosphorylation of Foxc2. 
Nat Commun. 2015; 6:7274.
MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition 
 
Lina S. Schneidera, Melanie Ulricha, Thorsten Lehrb, Dirk Menchec, Rolf Müllerd, 
Angelika M. Vollmara, Karin von Schwarzenberga 
 
aDepartment of Pharmacy, Pharmaceutical Biology, Ludwig-Maximilians-University of 
Munich, Butenandtstrasse 5-13, 81377 Munich, Germany 
bClinical Pharmacy, Saarland University, Campus C2 2, 66123 Saarbrücken, 
Germany 
cKekulé Institute of Organic Chemistry and Biochemistry, University of Bonn, 
Gerhard-Domagk-Str. 1, 53121 Bonn, Germany 
dSaarland University, Helmholtz Institute for Pharmaceutical Research Saarland, 
Helmholtz Centre for Infection Research and Department of Pharmaceutical 
Biotechnology, PO 151150, 66042 Saarbrücken, Germany 
Corresponding author: Dr. Karin von Schwarzenberg, Department of Pharmacy, 
Butenandtstrasse 5-13, 81377 Munich, Germany, Phone: +49-89-2180-77165, Email: 
karin.von.schwarzenberg@cup.uni-muenchen.de 
Conflict of interest: There is no conflict of interest. 
Abbreviations: 1 vacuolar-type ATPase, 2 oxidative phosphorylation, 3 TP53-induced 
glycolysis and apoptosis regulator, 4 U87MG, 5 insulin-like growth factor-binding 
protein 3 
    
ABSTRACT 
Treating cancer is one of the big challenges of this century and it has become 
evident that single chemotherapeutic treatment is rarely effective. As tumors often 
carry multiple mutations using combination therapy which addresses different targets 
seems therefore more beneficial. One of the most frequently mutated genes in 
tumors is the tumor suppressor p53. A lot of work has been put in the development of 
p53 activators, which are now in clinical studies against diverse cancers. Recently, 
we could show that inhibition of V-ATPase, a multisubunit proton pump, by archazolid 
induces p53 protein levels in cancer cells. In this study, we provide evidence that the 
combination of archazolid with the p53 activator nutlin-3a is synergistically inducing 
cell death in different p53 wild type tumor cell lines. Mechanistically, this effect could 
presumably be attributed to reduction of glycolysis as TIGAR mRNA levels were 
increased and glucose uptake and Glut1 protein levels were reduced. In addition, 
combination treatment highly activated pro-apoptotic pathways including IGFBP3 and 
Bax inducing caspase-9 and PARP cleavage. Remarkably, combination of archazolid 
and nutlin-3a was more efficient in reducing tumor growth compared to single dose 
treatment in a U87MG mouse model in vivo. Hence, our findings suggest the 
combination of archazolid and nutlin-3a as a highly promising strategy for the 
treatment of p53 wild type tumors.   
 
Keywords: cancer, therapy, p53, V-ATPase, nutlin-3a 
1. INTRODUCTION 
Cancer is a major health problem worldwide. It remains the second most common 
cause of death in the United States (Siegel et al., 2015). The development of tumors 
is a multistep process involving four to seven independent mutations in most cancers. 
Targeting only one pathway in this complex disease network is, in many cases, 
insufficient to combat cancer. Hence, in these cases, combination drugs with multiple 
targets might be necessary to gain optimal therapeutic benefit (Zimmermann et al., 
2007).   
Recently, our group introduced archazolid, a myxobacteria-derived vacuolar-
type ATPase (V-ATPase)1 inhibitor (Bockelmann et al., 2010; Huss et al., 2005; 
Menche et al., 2007; Sasse et al., 2003), as a promising new anti-cancer agent 
(Schneider et al., 2015; von Schwarzenberg et al., 2012; Wiedmann et al., 2012). V-
ATPases are multisubunit proton pumps expressed on endolysosomal membranes of 
almost all eukaryotic cells. They are responsible for maintaining the cellular pH 
homeostasis and play an important role in the regulation of receptor-mediated 
recycling (Hinton et al., 2009). In vitro experiments with different cancer cells showed 
a high cytotoxic potential of archazolid (Schneider et al., 2015; von Schwarzenberg et 
al., 2012). Mechanistically, V-ATPase inhibition blocked the iron metabolism of 
cancer cells resulting in altered glucose metabolism and p53 stabilization. In mouse 
experiments we could show that archazolid treatment reduced the tumor burden, 
however it was not successful in abrogating tumor growth completely (Schneider et 
al., 2015). This matter asked for a rational and innovative combination strategy, to 
achieve a better therapeutic efficacy for archazolid. Based on our previously 
published finding that archazolid stabilizes p53, we decided to combine in this study 
archazolid with the small molecule p53 activator nutlin-3a, which inhibits binding of 
p53 and MDM2 (Vassilev et al., 2004). 
The transcription factor p53 is one of the most studied tumor suppressors 
which plays a key role in maintaining genomic stability. In normal unstressed cells, 
p53 is expressed at a low level controlled by its negative regulators like MDM2. p53 
gets activated in response to a variety of stress signals including DNA damage, 
hypoxia or activation of oncogenes (Brooks and Gu, 2006; Vousden and Prives, 
2009). It is frequently mutated in human tumors and best known for regulating cell 
cycle arrest, senescence and apoptosis (Khoo et al., 2014).  
Interestingly, in recent years, it has become obvious that p53 also plays a 
pivotal role in regulating tumor metabolism, which strongly contributes to its tumor 
suppressing abilities. It regulates glycolysis, pentose phosphate pathway, oxidative 
phosphorylation (OXPHOS)2 and lipid metabolism and can counteract many of the 
metabolic alterations associated with cancer development. Repression of glycolysis 
and activation of OXPHOS are the major metabolic functions of p53 which lead to 
tumor growth inhibition (Berkers et al., 2013). p53 activation not only directly inhibits 
glucose receptor transcription (Schwartzenberg-Bar-Yoseph et al., 2004) but also 
leads to an upregulation of TP53-induced glycolysis and apoptosis regulator 
(TIGAR)3, which inhibits glycolysis by decreasing fructose-6-bisphosphate 
concentration (Bensaad et al., 2006).  
Our work unveils that combination of archazolid and nutlin-3a is highly efficient 
in inducing cell death in vitro and in reducing tumor growth in vivo in p53 positive 
tumors. This is mediated by counteracting the pro-glycolytic activities of archazolid 
leading to a decrease of glycolysis-related parameters which may contribute to the 
increased cell death induction. This work provides new insight in the role of V-
ATPase in tumor metabolism and proposes targeting the metabolic changes with 
nutlin-3a as a promising way for cancer therapy. 
2. MATERIAL AND METHODS 
2.1 Cell lines and reagents 
The mammary cancer cell line MCF7, the liver carcinoma cell line HepG2 and the 
cervical cancer cell line Hela were recently purchased from DSMZ (Braunschweig, 
Germany). The mammary cancer cell line MDA-MB-231 was obtained from Cell Line 
Service Eppelheim (Germany). The glioblastoma cell line U87MG (U87)4 was a kind 
gift from Prof. Adrian L. Harris (Department of Oncology, Wheatherall Institute of 
Molecular Medicine, Oxford University). MCF7 cells were cultivated in RPMI 1620 
complimented with 10% FCS, 1% nonessential amino acids, 1% pyruvate and 
125µg/L insulin. HepG2 and MDA-MB-231 cells were grown in DMEM High Glucose 
containing 10% FCS, Hela and U87 cells in RPMI 1620 supplemented with 10% 
FCS. Archazolid was isolated by Prof. Dirk Menche (Kekulé-Institute of Organic 
Chemistry and Biochemistry, University of Bonn, Bonn, Germany). Nutlin-3a was 
purchased from Sigma Aldrich (Taufkirchen, Germany).  
2.2 Immunocytochemistry 
2 x 104 MCF7 cells were seeded onto µ-slides 8-well ibidiTreat (IBIDI, Martinsried, 
Germany) and were treated as indicated. Then, cells were fixed with 4% 
paraformaldehyde (PFA), permeabilized with 0.2% Triton X-100/PBS and blocked 
with 1% BSA/PBS containing 0.1% Triton X-100. Antibody against p53 (Cell 
Signaling Technology, Danvers, MA) and AlexaFluor 488-goat-antimouse (Invitrogen, 
Waltham, MA) were diluted in blocking solution. Nuclei were stained with Hoechst 
33342® (Hoechst) (Sigma Aldrich). 
2.3 Western blot 
Western blot analysis was performed as described before (Schneider et al., 2015). 
Following antibodies were used: p53, pAkt Ser473, Akt, Bid, caspase-9, PARP (Cell 
Signaling Technology), Glut1 (Novus, Littleton, CO), IGFBP3, HRP goat-antimouse 
(Santa Cruz Biotechnology, Heidelberg, Germany), Rb (BD Bioscience, Heidelberg, 
Germany), Bcl-2 (Calbiochem, Darmstadt, Germany), AIF (Chemicon, Billerica, MA), 
actin (Millipore, Darmstadt, Germany) and HRP-goat-antirabbit (Bio-Rad, Munich, 
Germany). 
2.4 qPCR 
RNA extraction, cDNA synthesis and qPCR were performed as described before 
(Schneider et al., 2015). All designed primers were purchased from Metabion 
(Planegg, Germany). 
2.5 Cell death analysis 
Cell death was assessed as described elsewhere (Schneider et al., 2015).  
2.6 Measurement of metabolic activity 
CellTiter-Blue Assay (Promega, Mannheim, Germany) was performed according to 
the manufacturer`s protocol to quantify metabolic activity.  
2.7 Measurement of glucose uptake, ATP levels, Bax activation  
Quantifications were performed as reported previously (von Schwarzenberg et al., 
2012).  
2.8 In vivo mouse model 
For in vivo studies, six-week old female BALB/cOlaHsd-Foxn1nu/Foxn1+ mice (Harlan, 
Indianapolis, IN) were used. 5 x 106 U87MG cells were resuspended in PBS/matrigel 
(Corning, Wiesbaden, Germany) (1:1) and injected subcutaneously into the flank of 
each mouse. After formation of palpable tumors, mice were divided into groups and 
treated daily intraperitoneally with 0.2 mg/kg archazolid in 5% DMSO/10% 
solutol/PBS, 5 mg/kg nutlin-3a 5% DMSO/10% solutol/PBS, with both or solvent 
respectively. Measurement of tumors was done every 2 to 3 days with a caliper using 
the formula a x b2/2. Modeling was performed using the non-linear mixed effects 
modeling technique with the software NONMEM 7.3 (Simeoni et al., 2004). Nutlin-3a 
PK model was built based on literature data (Zhang et al., 2010). Tumor growth 
curves were normalized to control. Animal experiments were approved by the District 
Government of Upper Bavaria in accordance with the German animal welfare and 
institutional guidelines.  
2.9 Statistical analysis 
For all statistics GraphPad Prism was used. Error bars display SEM, except in vivo 
tumor growth curves which show SD. Synergism was calculated with the Bliss 
formula v=xcombination/((xA-xB)-(xA*xB)) with v>1 indicating synergism.  
3. RESULTS 
3.1 Combination of archazolid and nutlin-3a strongly induce p53 
We could recently show that the V-ATPase inhibitor archazolid induces p53 protein 
expression in breast cancer cells (Schneider et al., 2015). To start with, Fig. 1A 
shows that while low dose archazolid had no effect on p53 protein level, a 
combination with nutlin-3a even raises p53 protein levels over the level of nutlin-3a 
alone. To more deeply investigate this phenomenon, we analyzed the translocation 
of p53 to the nucleus – a prerequisite for p53 to be activated. We found that p53 is 
mostly located in the cytoplasm of untreated cells whereas it partially translocates to 
the nucleus after high dose archazolid treatment as well as after nutlin-3a treatment. 
Interestingly, a combination of the two compounds led to an almost complete 
reduction of cytosolic p53 and showed only activated p53 in the nucleus (Fig. 1B). 
This increased activation is due to stabilization of the protein and not enhanced 
transcription as there is no elevated mRNA level after combined treatment with 
archazolid and nutlin-3a (Fig 1C). Taken together, these findings indicate that 
combination of archazolid and nutlin-3a might have an improved anti-tumor activity in 
wild type p53 cells compared to the two compounds alone.  
3.2 Combination of archazolid and nutlin-3a induces synergistic cell death in 
cancer cells 
To analyze weather the increased p53 activation by archazolid and nutlin-3a has an 
effect on cell death induction, we used different p53 wild type tumor cell lines and 
one breast cancer cell line with mutated p53 and treated them with single drugs and 
combination. Subsequent flow cytometry analysis showed for MCF7, Hela and 
HepG2 cells synergistic cell death induction after combination treatment and for the 
glioblastoma cell line U87 reduced metabolic activity (Fig. 2A). As expected, 
combination treatment in MDA-MB-231 cells, which have mutated p53, did not show 
any effects (Fig.2B). These results suggest that the synergistic cell death induction 
depends on p53 activation. 
3.3 Treatment with combination of archazolid and nutlin-3a reduces glycolysis 
To find a molecular explanation for the synergistic effects of archazolid and nutlin-3a, 
we investigated the cellular glucose metabolism since p53 has effects on tumor 
metabolism (Madan et al., 2012; Matoba et al., 2006; Schwartzenberg-Bar-Yoseph et 
al., 2004). Firstly, mRNA expression levels of TIGAR were analyzed in MCF7 cells. 
TIGAR is a known target of p53 and reduces glycolysis by lowering levels of the 
glycolytic intermediate fructose 2,6-bisphosphate (Bensaad et al., 2006). Archazolid 
alone slightly downregulated TIGAR mRNA levels and nutlin-3a showed as expected 
a strong induction. Interestingly, combination of the two drugs led to a 14-fold 
induction of TIGAR which is even higher than nutlin-3a alone (Fig. 3A). A long this 
line, combination of archazolid and nutlin-3a showed reduced glucose uptake (Fig. 
3B) and Glut1 protein levels in MCF7 cells (Fig. 3C), which is not the case for each 
drug alone. Furthermore, archazolid increases the mRNA level of aldolase c, a key 
enzyme in glycolysis, which was diminished by combination with nutlin-3a (Fig. 3D). 
Consistently, ATP levels were strongly reduced in MCF7 cells treated with 
combination of archazolid and nutlin-3a (Fig. 3E). These observations indicate that 
nutlin-3a counters the pro-glycolytic activities of archazolid.  
3.4 Combination treatment targets apoptotic pathways 
Next, we wanted to connect the inhibition of glycolysis, mediated by combination of 
archazolid and nutlin-3a, with the apoptosis-inducing properties. First, we analyzed 
the expression of the p53 target proteins insulin-like growth factor-binding protein 3 
(IGFBP3)5 and Rb. Both can inhibit glycolysis and Akt (Clem and Chesney, 2012; Elzi 
et al., 2012; Lee et al., 2004) and can lead to apoptosis induction or growth arrest 
(Elzi et al., 2012; Fan and Steer, 1999; Lee et al., 2004). We could show that the 
combination of archazolid and nutlin-3a leads to a strong induction of IGFBP3 and 
dephosphorylation of Rb (Fig. 4A, B). This effect is accompanied by an inhibition of 
Akt phosphorylation (Fig. 4C). Interestingly, both drugs alone did not show an 
inhibitory effect on Akt. In addition, combination strongly increases active Bax levels 
(Fig. 4D), but had no effect on Bcl-2, Bid and AIF (Fig. 4E). Finally, cleavage of 
caspase-9 (Fig. 4F) and PARP (Fig. 4G) is induced, altogether suggesting activation 
of pro-apoptotic pathways.  
3.5 Combination of archazolid and nutlin-3a reduces tumor growth in vivo 
Finally, to prove that combination of archazolid and nutlin-3a is efficient in reducing 
tumor growth in vivo we performed a xenograft mouse model using U87MG cells. 28 
female SCID mice were treated with archazolid 0.2mg/kg, nutlin-3a 5mg/kg or 
combination over 17 days and tumor burden was measured and normalized to 
control (Fig. 5A). Growth rate of tumors treated with combination was significantly 
reduced compared to control. Moreover, combination was most effective in reducing 
tumor volume (50.4%). Along this line, tumors treated with combination showed 
highest doubling times (Fig.5B). These data render combination of archazolid and 
nutlin-3a promising and attractive strategy for the treatment of p53 wild type tumors.  
4. DISCUSSION 
Our study suggests combination of the V-ATPase inhibitor archazolid with the p53 
activator nutlin-3a as a promising and viable strategy for the treatment of p53 wild 
type tumors and reveals novel insights into archazolid’s mode of action.  
 Cancer is a multigenic disease. The process of oncogenesis requires in most 
tumors four to seven mutations. As only a few single-target drugs are able to 
efficiently combat this disease, a change to multi-target therapeutics has occurred in 
recent years. Combination drugs can be more efficient in controlling complex 
diseases and can overcome drug resistance. For example, patients suffering from 
breast cancer benefit from a combination of trastuzumab, targeting ErbB2, with the 
anti-VEGF antibody Avastin®. Along this line, multi-target therapies with traditional 
chemotherapeutics are well established in the clinical treatment of cancers 
(Zimmermann et al., 2007).  
In the last decade, a lot work was done to explore the anti-tumor activity of V-
ATPase inhibitors. Various reports prove the cytotoxic activity of V-ATPase inhibitors 
such as bafilomycin, concanamycin and archazolid in diverse cancer cell lines in vitro 
(Koul et al., 2013; Nakashima, 2003; Ohta et al., 1998; Schneider et al., 2015; von 
Schwarzenberg et al., 2012; Wu et al., 2009). In vivo experiments revealed the anti-
metastatic potential of archazolid (Wiedmann et al., 2012) and NiK-12192, a small 
molecule V-ATPase inhibitor (Supino et al., 2007). However, treatment of solid 
tumors with V-ATPase inhibitors showed only weak effects in vivo. Treatment of 
Capan-1 tumors with bafilomycin showed a reduction of tumor growth only in high 
doses and tumors over 300mm3 (Ohta et al., 1998). Lim et al. reported that tumor 
growth inhibition by bafilomycin is more effective in larger HIF1α-positive tumors (Lim 
et al., 2006). Moreover, the high toxicity of V-ATPase inhibitors was thought to be 
prohibitive for clinical use (Drose and Altendorf, 1997). Nevertheless, inhibition of V-
ATPase was shown to overcome chemoresistance in vitro (Sasazawa et al., 2009; 
You et al., 2009) and trastuzumab resistance in vivo (von Schwarzenberg et al., 
2014). 
As our own recently published work showed only a moderate reduction of 
tumor burden in vivo after archazolid treatment, we now intended to improve this by a 
rational combination approach. There are several ways for multi-target therapies to 
achieve better therapeutic efficacy, one is to address different targets within the same 
pathway (Zimmermann et al., 2007). Since our study further revealed that archazolid 
interferes with the iron metabolism of cells finally resulting in disturbed glucose 
metabolism and p53 stabilization (Schneider et al., 2015), combination treatment 
within the p53 pathway seemed promising.  
p53 was extensively studied in the last decades as it is the most frequently 
mutated gene in tumors. Nevertheless, about half of all human cancers carry no 
mutation in this gene. Therefore, a lot of work has been put in the development of 
p53 activators, which are now in clinical studies against diverse cancers. One very 
promising approach is to activate p53 through small molecule MDM2 antagonists. In 
order to restore p53 function, in cases where it is mutated, efforts have been made to 
identify drugs which stabilize p53 conformation by acting as p53 chaperones through 
binding to it. Moreover, gene therapy has been used to manipulate the p53 network 
(Khoo et al., 2014).  
In search for compounds that are able to block the p53-MDM2 binding, 
thereby activating p53, Vassilev et al. identified a class of small molecules named 
nutlins. They could show that nutlin-3 was efficient in reducing tumor growth of SJSA-
1 xenografts (Vassilev, 2004) and others revealed its antitumor activity in MHM, 
LnCap and 22Rv1 xenografts (Tovar et al., 2006). Moreover, efficient reduction of 
tumor growth was shown in combination studies. For example targeting MDM2 with 
nutlin-3 showed superior in vivo efficacy in leukemia when combined with valproic 
acid, which inhibits histone deacetylases (McCormack et al., 2011). To address the 
p53 pathway at two different points, we combined in this study archazolid with nutlin-
3a in different cancer cell lines. p53 wild type tumor cells showed synergistic cell 
death induction in vitro while p53 mutant cells showed no effect, suggesting a p53 
dependent mechanism.   
Despite regulating cell cycle arrest, senescence and apoptosis, p53 is known 
to act on metabolism of cells, which contributes to its tumor suppressing abilities 
(Berkers et al., 2013). Interestingly, V-ATPase function was also connected to tumor 
metabolism. Recently, we could show that archazolid has an impact on the glucose 
metabolism of cancer cells (Schneider et al., 2015). In addition, others demonstrated 
that V-ATPase acts as a metabolic sensor by playing a role in amino acid sensing via 
mTOR and by physical interaction with glycolytic enzymes (Maxson and Grinstein, 
2014; Zoncu et al., 2011). Along this line, we found decreased ATP levels – 
indicating insufficient energy supply – by the combination therapy as well as reduced 
glucose uptake and receptor expression, which can lead to a lowered glycolytic flux. 
In addition, mRNA levels of the p53 target TIGAR, recently identified to decrease 
fructose-6-bisphosphate concentration, and thereby glycolysis (Bensaad et al., 2006), 
were 14-fold increased after combination treatment. This was accompanied by 
reduced levels of the glycolytic intermediate aldolase further proposing that the 
combination counteracts glycolysis.  
Moreover, other proteins, which have been associated with p53, were 
influenced by the combination of archazolid and nutlin-3a. The protein level of the 
IGF-related tumor suppressor IGFBP3 (Buckbinder et al., 1995), which was shown to 
attenuate tumor growth in different studies (Alami et al., 2008; Butt et al., 2000; Silha 
et al., 2006; Williams et al., 2000), was strongly increased. This was accompanied by 
reduced phosphorylation of Akt. Interestingly, a probable connection between 
IGFBP3 and the Akt pathway was described before (Alami et al., 2008). In addition, 
combination treatment influenced a further player in the p53 network as it strongly 
dephosphorylates and activates Rb. Rb is best known for leading to cell cycle arrest 
as it gets increasingly phosphorylated during G1 and is hypophosphorylated in 
resting cells (Giacinti and Giordano, 2006).  
One of the most studied functions of p53 is its ability to induce apoptosis in 
response to a variety of stress signals. As a consequence, transcriptionally active 
p53 can simultaneously target distinct pathways in the apoptotic network. For 
example, it regulates the expression of pro-apoptotic members of the Bcl-2 family, 
such as Bax, Puma or Bid. As a result of the predominant emergence of pro-
apoptotic proteins, caspase activation and apoptosis is induced (Fridman and Lowe, 
2003). In this study, combination of archazolid and nutlin-3a results in a synergistic 
activation of the pro-apoptotic protein Bax and a subsequent cleaveage of caspase-3 
and PARP. Although p53 can target the apoptotic signaling cascade at several 
points, apoptosis induction via Bax seems to be specific as we could find no effect on 
Bcl-2, Bid or AIF, which are also p53 target proteins. 
Most importantly, the combination of nutlin-3a and archazolid not only showed 
an effect in vitro but also strongly reduced growth of a wild type p53 glioblastoma 
xenograft mouse model compared to each drug alone. 
Taken together, targeting the p53 pathway at two distinct points with 
archazolid and nutlin-3a unveiled strong tumor-inhibiting capabilities in vitro and in 
vivo in p53 wild type tumor cells. Mechanistically, combination treatment affects 
several parts in the p53 network: it reduces glycolysis, activates Bax, induces 
IGFBP3, dephosphorylates Rb and finally induces apoptosis. These results suggest 
combination of archazolid and nutlin-3a as a highly promising treatment for p53 wild 
type tumors and opens up new therapeutic options for V-ATPase inhibitors.   
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 FIGURE LEGENDS 
Fig.1: p53 translocates to the nucleus in archazolid- and nutlin-3a-treated MCF7 
cells. (A) p53 protein levels were analyzed by western blot in MCF7 cells after 24 h 
of treatment. (B) p53 and nuclei were stained in permeabilzed MCF7 cells after 24 h 
of indicated treatment. Pictures of cells were taken with confocal microscopy. Scale 
bars, 10 µm. (A, B) Representative experiments out of three independent 
experiments are shown. (C) p53 mRNA levels were quantified by qPCR in MCF7 
cells after 24 h of treatment. Bars are the SEM of three independent experiments 
performed in duplicate.  
Fig.2: Archazolid and nutlin-3a synergistically induce cell death in p53 wild 
type tumor cells. (A, B) Cell death induction after archazolid and nutlin-3a treatment 
(48 h in MCF7, Hela and MDA-MB-231cells; 24 h in HepG2 cells) was assessed by 
flow cytometry (quantification of PI-permeable cells for MCF7, Hela and HepG2 cells; 
quantification of SubG1 for MDA-MB-231 cells). Metabolic activity of U87 cells was 
analyzed by Cell Titer Blue assay. Bars are the SEM of three independent 
experiments performed in triplicate. Synergism was calculated with the Bliss formula 
(values: 1,59 for MCF7; 2,45 for Hela; 2,43 for HepG2 and 1,25 for U87).  
Fig.3: Reduced glycolysis in cells treated with archazolid and nutlin-3a. (A, D) 
qPCR analysis was performed in MCF7 cells to quantify TIGAR and aldolase c 
mRNA levels after 24 h of treatment. Bars are the SEM of three independent 
experiments performed in duplicate. (B) To assess glucose uptake, flow cytometry 
analysis was performed after 8 h of treatment in MCF7 cells. Therefore, cells were 
incubated with 100 μM 2-NBDG (2-[N-(7-Nitrobenz-2-Oxa-1,3-Diazol-4-yl)Amino]-2-
Deoxy-D-Glucose) in HANKS buffer for 30 min at 37 °C. Synergism was calculated 
with the Bliss formula (value: 1,05).  (C) Western blot analysis was performed in 
 MCF7 cells after 48 h of treatment to detect Glut1 protein levels. One representative 
experiment out of three independent experiments is shown. (E) ATP levels were 
determined by Cell Titer Glow assay. Therefore, MCF7 cells were treated with 
archazolid and nutlin-3a for 24 h, subsequently incubated with CTG and analyzed 
with a luminometer. Synergism was calculated with the Bliss formula (value: 1,32). 
(B, E) Bars are the SEM of three independent experiments performed in triplicate.  
Fig.4: Combination treatment targets apoptotic pathways including IGFBP3 and 
Bax. (A-C, E-G) MCF7 cells were treated for 24 h and western blot analysis was 
performed to detect IGFBP3, Rb (48 h), pAkt, Akt, Bcl-2, Bid, AIF, caspase-9, PARP 
(48 h), tubulin and actin protein levels. Representative experiments out of three 
independent experiments are shown. (D) Flow cytometry analysis was used to 
quantify active Bax levels after 24 h of archazolid and nutlin-3a treatment in MCF7 
cells. Bars are the SEM of three independent experiments performed in triplicate. 
Synergism was calculated with the Bliss formula (value: 3,13). 
Fig.5: Combination of archazolid and nutlin-3a efficiently reduces tumor growth 
of U87 cancer cells in vivo. (A) U87 tumor cells were subcutaneously injected into 
the flanks of 28 SCID mice (co: n=6; arch: n=7; nutlin-3a: n=7; combination: n=8). 
Mice were treated daily intraperitoneally with 0.2 mg/kg archazolid, 5 mg/kg nutlin-3a, 
both or equal amounts of solvent. Tumor growth curves are normalized to control. 
Bars display SD. (B) Growth rate, reduction and doubling time were calculated from 
data in Fig. 5A. Growth rate was calculated based on control growth rate. Reduction 
is in relation to control.  
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 Two-pore channel function is crucial for migration of invasive cancer cells 
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 ABSTRACT 
Metastasis is the main cause of cancer-related deaths. Hence, there is an urgent 
need to find new therapies. In this study, we introduce a promising new target for the 
treatment of invasive cancers. Inhibition of two-pore channels (TPCs), recently 
identified NAADP- and PI(3,5)P2-sensitive Ca
2+-permeable cation channels in the 
endolysosomal system of cells, abrogated migration of metastatic cancer cells in 
vitro. Remarkably, tetrandrine, lately discovered to inhibit TPCs, showed in vivo 
efficacy reducing lung metastasis of mammary mouse cancer cells. As a molecular 
explanation, we found that disrupting TPC function halted β1-integrin trafficking, 
leading to accumulation in EEA1-positive vesicles. This is suggested to be due to 
alterations in Ca2+ signaling since pH was not affected. As a consequence, invasive 
cancer cells are no longer able to form leading edges, which is substantially required 
for adequate migration. Our study links TPCs to fundamental processes in cancer cell 
migration proposing that they are promising novel targets for the treatment of 
metastatic cancers. 
 
 
 INTRODUCTION 
Metastasis is the major cause of cancer-related deaths. The formation of secondary, 
metastatic growth includes proliferation and extensive vascularization of the primary 
tumor, detachment and invasion of tumor cells, circulation of single tumor cells, arrest 
in distant sites, extravasation and finally proliferation within the organ (Fidler, 2003). 
Extensive studies in the last decades contributed to a better understanding of these 
processes. However, still about 90% of cancer-associated mortality is due to 
metastasis. Therefore, new strategies to prevent metastasis are urgently needed 
(Chaffer & Weinberg, 2011; Fidler, 2003). 
 To successfully colonize secondary sites, cancer cells gained the ability to 
migrate (Chaffer & Weinberg, 2011; Hood & Cheresh, 2002). A crucial step in 
migration is the binding to ligands of the extracellular matrix (ECM), which is 
mediated by integrins. These cell surface receptors display a diverse family of 
glycoproteins consisting of 18 α-subunits and 8 β-subunits. Besides mediating cell 
attachment to the ECM, integrins are linked to the cytoskeleton through the formation 
of clusters with actin-associated proteins such as vinculin. Furthermore, ligation of 
integrins induces a network of intracellular signaling pathways including the activation 
of focal adhesion kinase (FAK) and Src, altogether regulating cell migration (Hood & 
Cheresh, 2002). 
 In order to fulfill the function as migration-promoting receptors, integrins have 
to be trafficked to the front of the cell for assembly of focal adhesions. These 
adhesions act as traction sites for the movement and are afterwards disassembled at 
the rear of the cell, for detachment. Hence, integrins need to be dynamically turned 
over, which is achieved by endocytic trafficking (Maritzen et al, 2015; Ridley, 2003). 
After endocytosis, integrins are carried to early endosomes where sorting into 
recycling and degradative pathways takes place. Under normal conditions, the larger 
 portion recycles back to the plasma membrane. Disturbing this process can alter the 
composition of focal adhesions, thereby influencing cell migration (Maritzen et al, 
2015). 
 There is increasing evidence that two-pore channels (TPCs) are key players in 
the regulation of endocytic transport (Brailoiu et al, 2009; Calcraft et al, 2009; Zong et 
al, 2009). It has been postulated that inhibiting these channels alters Ca2+ signaling 
during endolysosomal fusion events resulting in defects in vesicle trafficking (Grimm 
et al, 2014; Ruas et al, 2010; Ruas et al, 2014). TPCs are assigned to the 
superfamily of voltage-gated ion channels (Calcraft et al, 2009). There are two 
different TPC subtypes present in primates, TPC1 and TPC2. TPC1 is primarily 
expressed on endosomal membranes while TPC2 dominates on lysosomal 
membranes (Calcraft et al, 2009; Rietdorf et al, 2011; Ruas et al, 2010). Activation of 
these channels is presumably triggered by the second messenger nicotinic acid 
adenine dinucleotide phosphate (NAADP) and by phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P2) (Calcraft et al, 2009; Jha et al, 2014; Schieder et al, 2010; 
Wang et al, 2012). Distinct experiments suggested TPCs as Ca2+-permeable 
channels indicating that TPCs might be involved in Ca2+ release from endo- and 
lysosomal stores (Calcraft et al, 2009; Grimm et al, 2014; Ruas et al, 2015; Schieder 
et al, 2010; Zong et al, 2009). 
 This work unveils that TPCs play a crucial role in the formation of metastasis 
as silencing TPC1 and TPC2 reduced the adhesion and migration of invasive tumor 
cells in vitro. Similar results were achieved with Ned-19, an antagonist of NAADP 
(Naylor et al, 2009), and tetrandrine, recently shown to inhibit TPC1 and TPC2 
(Sakurai et al, 2015). Remarkably, the latter showed efficacy in a metastatic in vivo 
model. Inhibition of TPCs led to the accumulation of integrins in endocytic vesicles 
 and to impaired formation of leading edges indicating that TPCs are significantly 
involved in integrin recycling. 
 RESULTS 
TPCs in cancer cells 
TPCs have been described in different cell types (Favia et al, 2014; Grimm et al, 
2014; Sakurai et al, 2015), however not in cancer cells so far. TPC2 mRNA is 
distinctly expressed in T24 (bladder cancer), Jurkat (leukemia) and HUH7 (HCC) 
cells (Fig. 1A). mRNA levels of TPC1 were particularly high in T24 and HUH7 cells 
(Fig. 1B). Tumor tissue sections of HCC patients showed a highly positive staining for 
TPC2 (Fig. 1C). Together, these data suggest the presence of TPCs in cancer cells. 
To verify TPC functionality in T24 cancer cells, we isolated lysosomes and performed 
endolysosomal patch-clamp experiments. The applied whole-endolysosmal patch-
clamp method is illustrated in Fig. 1D. PI(3,5)P2-elicited currents were strongly 
reduced after applying tetrandrine (Fig. 1E, F), recently shown to inhibit TPC1 and 
TPC2 (Sakurai et al, 2015). 
TPCs affect cancer cell migration and adhesion 
Previous studies in TPC2-deficient MEF cells showed defects in the endolysosmal 
degradation pathway (Grimm et al, 2014; Ruas et al, 2014). As alterations in this 
pathway through inhibition of another endolysosome-associated protein, the vacuolar 
ATPase (V-ATPase), have been described to reduce the ability of invasive cancer 
cells to migrate (Wiedmann et al, 2012), we hypothesized that TPCs affect cancer 
cell migration. Silencing TPC1 and TPC2 by siRNA in T24 cells resulted in 
significantly reduced migration through pores in Boyden chamber assays (Fig. 2A). 
Knockdown efficiency is shown in Fig. 2B. Moreover, these cells showed diminished 
adhesion after 1 h of seeding (Fig. 2C). To get more information about the migratory 
defect, movement of silenced cells exposed to a diffusive gradient of FCS (0 to 10%) 
was analyzed. Figure 2 D shows control cells moving clearly towards the highest 
 FCS concentrations whereas knockdown cells displayed reduced directional 
migration, which is expressed as pValue in the Rayleigh test. Not only directed 
migration but also cell mobility seems to be affected as velocity was significantly 
reduced in silenced cells. Thus, TPC1 and TPC2 seem to play a pivotal role in two 
major steps of metastasis formation: adhesion and migration. 
Pharmacological inhibition of TPC1 and TPC2 reduces cancer cell migration 
To further investigate the potential of TPCs as novel targets for cancer therapy, two 
pharmacological inhibitors of TPC1 and TPC2 were used. The NAADP antagonist 
Ned-19 (Naylor et al, 2009) showed significant reduction of migration through pores 
in T24 and HUH7 cells (Fig. 3A). Along this line, treatment with tetrandrine abrogated 
migration in Boyden chambers in T24, HUH7 and 4T1 cells (Fig. 3B). Importantly, 
Ned-19 and tetrandrine had no effect on cell survival in all tested concentrations and 
at all tested time points (Fig. 3C). These results strengthen our finding that TPC1 and 
TPC2 are required for migration of cancer cells. 
Accumulation of enlarged acidic vesicles after Ned-19 treatment 
As TPC1 and TPC2 are located in the endolysosomal system (Calcraft et al, 2009; 
Rietdorf et al, 2011; Ruas et al, 2010) of cells, investigating this process after 
inhibition of TPCs seemed mandatory. Firstly, membranes of cells were stained with 
PKH26 fluorescent dye and subsequently allowed to recycle. As Figure 4A indicates, 
cells treated with Ned-19 accumulated up to 3-fold enlarged vesicles compared to 
control cells indicating that general recycling was impaired after TPC inhibition. 
Staining with Lysotracker Red DND-99 showed that the accumulated enlarged 
vesicles are acidic compartments. This experiment further indicates that acidification 
of endocytic vesicles was not affected after Ned-19 treatment (Fig. 4B). However, 
alterations in calcium homeostasis may disturb trafficking of endosomes to 
 lysosomes (Grimm et al, 2014; Lu et al, 2013; Ruas et al, 2010). To this end, 
cytosolic calcium levels were measured with fura-2AM in cancer cells during TPC 
inhibition. Calcium release out of lysosomes was stimulated by nigericin. In contrast 
to control, tetrandrine-treated cells displayed no increase in cytosolic calcium levels 
(Fig. 4C), suggesting disturbed calcium homeostasis as possible cause of impaired 
recycling. 
Disturbed β1-integrin recycling through inhibition of TPCs 
Integrins feature prominently in cancer cell adhesion and migration. Under normal 
conditions these transmembrane receptors get rapidly recycled through the 
endolysosomal system (Maritzen et al, 2015). Since inhibition of TPCs hampered 
endocytosis, we checked whether recycling of β1-integrin is hindered as well. An 
internalization assay of β1-integrin in T24 cells showed a 3-fold enlargement of β1-
integrin positive vesicles after Ned-19 treatment compared to control (Fig. 5A). 
Moreover, staining of β1-integrin-positive vesicles with EEA1 and LAMP3 displayed a 
higher overlap of β1-integrin vesicles with EEA1, indicating an accumulation in early 
endosomes rather than lysosomes (Fig. 5B). In summary, these findings illustrate 
that β1-integrin recycling is disturbed after TPC inhibition. 
Polarization and protrusion of the cell are essential for accurate cell migration. 
Protrusions in the direction of migration are stabilized through integrins linked to the 
actin cytoskeleton. Therefore, integrins have to be recycled to the leading edges of 
migrating cells (Maritzen et al, 2015; Ridley, 2003). To explore the ability to form 
leading edges, scratch assays were performed. Under these conditions, Ned-19 
inhibited the formation of wound-directed, β1-integrin-, pSrc-, pFAK- and vinculin-
positive polarized lamellipodia (Fig. 6A). These findings can be easily accounted for 
by disturbed β1-integrin trafficking to the front of the cell. Consistently, total protein 
 levels of β1-integrin, FAK, pFAK, Src and pSrc were not significantly altered after 
Ned-19 treatment (Fig. 6B), further corroborating an effect on β1-integrin recycling. 
Reduced formation of lung metastasis in vivo by pharmacological TPC 
inhibition 
To extend the relevance of TPC inhibition on chemotactic migration and invasion, we 
investigated whether tetrandrine was effective in abrogating cancer cell dissemination 
in a mouse model. The 4T1-Luc syngeneic metastatic mouse mammary cancer 
model was used for this purpose (Aslakson & Miller, 1992; Tao et al, 2008; Yang et 
al, 2004). 4T1-Luc cells are expressing a luciferase reporter which enables for live 
imaging. After intravenous injection, 4T1-Luc cells disseminate to distant organs 
homing preferably to lungs. Along this line, control animals showed easily detectable 
lung metastasis after five days of 4T1-Luc cell injection. Remarkably, pretreatment 
with tetrandrine significantly diminished formation of lung metastasis (Fig. 7). These 
findings further support the hypothesis that targeting TPCs might be a very promising 
and viable strategy for metastatic cancer therapy. 
 DISCUSSION 
This study designates TPCs as promising targets for the treatment of invasive 
cancers. Disruption of TPC function abrogates cancer cell migration in vitro and in 
vivo, resulting from disturbed integrin trafficking in the endolysosomal system. 
 TPCs are Ca2+-permeable voltage-gated channels located in the membrane of 
endosomes and lysosomes (Calcraft et al, 2009; Grimm et al, 2014; Rietdorf et al, 
2011; Ruas et al, 2010; Ruas et al, 2015; Schieder et al, 2010; Zong et al, 2009). In 
recent years, evidence has accumulated that TPCs are substantially implicated in the 
regulation of endolysosomal trafficking. Thus, a lack of TPC2 in mouse embryonic 
fibroblasts resulted in an accumulation of LDL and EGF/EGFR in intracellular 
vesicles (Grimm et al, 2014) and led to delayed PDGFRβ degradation, which 
requires trafficking to lysosomes (Ruas et al, 2014). Overexpression of TPCs 
retained cholera toxin within endolysosomes, which is normally delivered to the Golgi, 
and enlarged lysosomes dramatically (Ruas et al, 2010). Disrupting TPC function 
also reduced Ebola virus trafficking through endosomal vesicles, preventing infection 
(Sakurai et al, 2015). Consistently, we observed an accumulation of integrins in early 
endosomes after TPC inhibition in invasive cancer cells. Alterations in Ca2+ signaling 
are widely accepted to lead to impaired trafficking and fusion of endocytic vesicles 
(Grimm et al, 2014; Ruas et al, 2010). This hypothesis is further supported by the 
finding that Ca2+ chelators, BAPTA and EGTA-AM, are able to inhibit fusion of late 
endosomes and lysosomes (Pryor et al, 2000). In this context, it is interesting to note 
that another Ca2+-permeable endolysosomal channel, TRPML1, has been proposed 
to be required for fusion between late endosomes and lysosomes in Drosophila 
(Wong et al, 2012). In humans, loss or mutation of this channel leads to the 
lysosomal storage disorder mucolipidosis type IV (Bargal et al, 2000; Chen et al, 
2014; Slaugenhaupt et al, 1999), further supporting the importance of Ca2+ signaling. 
  When looking at general endocytic trafficking and receptor recycling, another 
protein located in the endolysosmal membrane of cells comes into focus, the V-
ATPase. V-ATPases are multiunit proton pumps, which actively transport protons 
from the cytoplasm into intracellular compartments thereby regulating its pH (Forgac, 
2007). In several reports, it has been observed that altering pH by inhibition of V-
ATPase results in impaired trafficking and recycling of signaling molecules. Hence, 
disturbed V-ATPase function led to the accumulation of Notch in the endolysosomal 
system (Kobia et al, 2014) and of cholesterol in intracellular compartments (Kozik et 
al, 2012). In cancer cells, inhibition of V-ATPase affected EGF receptor (Wiedmann 
et al, 2012) and transferrin receptor internalization, the latter resulting in apoptosis 
(Schneider et al, 2015). 
 Taken together, targeting the endolysosmal system either by TPC or V-
ATPase inhibition can apparently both impair adequate endocytic trafficking. As it is 
quite evident for V-ATPase inhibition that this is due to altered pH, there is still an 
ongoing discussion regarding TPCs. As mentioned above, impaired Ca2+ signaling 
may be one reason, however it has also been postulated that alkalinizing of the 
lysosomal pH is responsible for the inhibition of autophagosomal-lysosomal fusion 
(Lu et al, 2013). In our study, we observed an accumulation of enlarged acidic 
vesicles after TPC inhibition, hence, no alkalinizing of pH. However, we found that 
tetrandrine completely halted intracellular Ca2+ release evoked by nigericin, 
suggesting that acute block of endolysosomal Ca2+ signaling might explain the 
observed trafficking defects. Other recent publications have also found no evidence 
for changes in endolysosomal pH under basal conditions in TPC-deficient cells (Cang 
et al, 2013; Grimm et al, 2014; Ruas et al, 2014). 
 Regardless of what the main cause of this impairment is, inhibition of TPC 
function led to a clear accumulation of β1-integrins in early endosomes. Integrins link 
 the cell to the ECM enabling adhesion and migration (Huttenlocher & Horwitz, 2011). 
To migrate, the cell must be polarized meaning that different molecular processes 
occur at the front and back of a moving cell (Ridley, 2003). Therefore, several 
proteins are trafficked towards the front of the cell. For example, growth factor 
receptors and chemokine receptors are recycled to specific sites of the leading edge 
to mediate pro-migratory signals. Importantly, adhesive contacts are regulated by the 
recycling and degradation of integrins (Maritzen et al, 2015). Hence, the turnover of 
integrins is crucial for migration. We could observe in our studies, in addition to an 
accumulation of β1-integrin in enlarged vesicles, reduced β1-integrin localization at 
the leading edge of migrating cells after TPC inhibition. These findings suggest that 
disrupted TPC function alters β1-integrin trafficking, resulting in reduced adhesion to 
ECM and insufficient polarization of the cell. 
Besides mediating adhesion to ECM, integrins are also essential for cell 
migration as they regulate pro-migratory signaling pathways. Thus, integrin ligation 
induces clustering, resulting in the activation of FAK. Active FAK recruits Src family 
kinases to focal adhesions, altogether promoting cell migration and invasion. In 
addition, focal contacts contain different actin-associated proteins such as vinculin 
which links integrin to the cytoskeleton (Hood & Cheresh, 2002). In our study, 
inhibition of TPC function clearly diminished the accumulation of integrin, pFAK, pSrc 
and vinculin at the leading edge of migrating cells. This suggests that adequate β1-
integrin trafficking is crucial for the initiation of pro-migratory mechanisms. 
To fulfill these functions, integrins form heterodimeric receptors. Pairing of α 
and β subunits decides for the specific binding of certain matrix ligands. Previous 
investigations on the β1-integrin subunit revealed a central role in adhesion, 
extravasation and migration in T24 cancer cells (Heyder et al, 2005). Moreover, 
reports show that β1-integrin and FAK signaling is implicated in the initial proliferation 
 of cancer cells disseminated into the lungs (Shibue & Weinberg, 2009). Our own 
experiments are consistent with these notions. Further research over the last several 
years led to the development of integrin targeted therapeutics, which are now tested 
in clinical studies against cancer and other diseases (Hood & Cheresh, 2002). The 
monoclonal antibody Volociximab is the first α5β1 integrin antagonist in clinical trials 
against metastatic clear cell renal cell carcinoma, metastatic melanoma, non-small 
cell lung cancer and peritoneal cancer among others (Almokadem & Belani, 2012; 
Millard et al, 2011). In addition, several therapeutic antibodies targeting αvβ3 integrin 
are under development or in clinical phases as anti-tumor agents such as Vitaxin and 
CNTO 95 (Millard et al, 2011). Taken together, targeting integrins is a highly 
promising and viable strategy for the treatment of metastatic cancers. 
Taken together, our study reveals a potential novel role for TPCs in the 
formation of metastasis. Impaired TPC function reduced adhesion and migration of 
cancer cells in vitro and diminished formation of metastasis in vivo. Most likely this is 
due to disturbed trafficking of integrins, known to act pro-migratory. Here we link 
TPCs to fundamental processes in cancer cell migration, rendering them new and 
attractive targets for the treatment of invasive carcinomas. 
  
 MATERIAL AND METHODS 
Cell lines and Reagents 
The cancer cell line T24 was obtained from Dr. B. Mayer (Surgical Clinic, LMU, 
Munich, Germany) and authenticated by the DSMZ, HUH7 were purchased from 
Japanese Collection of Research Bioresources and 4T1-Luc (4T1) from PerkinElmer. 
T24 cells were grown in McCoy’s, HUH7 cells in DMEM High Glucose and 4T1 cells 
in RPMI-1640 medium. All media were supplemented with 10% FCS. trans-Ned-19 
(Ned-19) was purchased from Tocris® Bioscience, tetrandrine from Santa Cruz 
Biotechnology. 
qRT-PCR 
qRT-PCR of TPC1 and TPC2 was performed as described previously (Schneider et 
al, 2015). Following primers were used: TPC2 fw 5’-GTA CCC CTC TTG TGT GGA 
CG-3’, rv 5’-GGC CCT GAC AGT GAC AAC TT-3’; TPC1 fw 5’-GGA GCC CTT CTA 
TTT CAT CGT-3’, rv 5’-CGG TAG CGC TCC TTC AAC T-3’; 
Whole-endolysosomal patch clamp 
Whole-endolysosomal patch-clamp recordings were performed by modified 
conventional patch-clamp. T24 cells were treated with 1 μM vacuolin-1 at least 4 h. 
Currents were recorded using an EPC-10 patch-clamp amplifier and PatchMaster 
acquisition software (HEKA, Lambrecht/Pfalz, Germany). Data were digitized at 40 
kHz and filtered at 2.8 kHz. Recording pipettes had a resistance of 8-10 MΩ. Liquid 
junction potential was corrected. Pipette solution (corresponding to luminal 
endolysosomal solution) contained 140 mM NaMSA, 5 mM KMSA, 2 mM CaMSA, 1 
mM CaCl2, 10 mM HEPES and 10 mM MES, pH 4.6. Bath solution (corresponding to 
cytosolic solution) contained 140 mM KMSA, 5 mM KOH, 4 mM NaCl, 0.39 mM 
CaCl2, 1 mM EGTA, and 10 mM HEPES, pH 7.2. PI(3,5)P2 was used in a water-
 soluble diC8 form (A.G. Scientific). All compounds including PI(3,5)P2 were prepared 
as high-concentration stock solutions, added to the bath solutions to match the final 
concentration indicated. pH of bath solution and pipette solution were adjusted with 
KOH and MSA, respectively. All recordings were obtained at 21-23 °C and were 
analyzed using PatchMaster and Origin 6.1 (OriginLab, Northampton, MA) software. 
Tissue staining 
2 μm tissue sections were used. Antigen retrieval was done with Target Retrieval 
Solution from Dako and sections were heated for 30 min in the microwave. Blocking 
of endogenous peroxidase was done in 7.5% hydrogen peroxide for 10 min. Anti-
TPC2 (atlas antibodies, diluted 1:60) was applied as primary antibody for 1 h at RT. 
For antibody detection, ImmPress™ reagent anti-rabbit Ig was utilized according to 
the manual and DAB+ for 3 min at RT was used as a chromogen. Slides were 
counterstained with hematoxylin for 20 sec and finally embedded in mounting 
medium and covered with glass coverslips. 
Cell transfection 
2x105 T24 cells were transfected using the ScreenFect® A Transfection Kit 
(Genaxxon bioscience). TPC1 and TPC2 were silenced using siRNA from Santa 
Cruz Biotechnology. Non-targeting siRNA was used as a control. 
Boyden chamber assay 
1x105 treated or silenced cells were placed on top of the Transwell® chamber 
(Corning) in media without FCS. 24-well plate was filled with medium with 10% FCS. 
Transwell® chambers were placed in it and incubated for 16 h. Migrated cells were 
fixed and stained with crystal violet/methanol. The top of the Transwell® chamber was 
cleaned and pictures were taken. Migrated cells were counted with Image J (National 
Institutes of Health). 
 Adhesion assay 
5x104 silenced T24 cells were seeded onto µ-slides 8-well ibidiTreat and allowed to 
attach for 1 h. Subsequently, cells were fixed with 4% paraformaldehyde (PFA) and 
stained with rhodamine-phalloidin (Molecular Probes®) and Hoechst 33342® 
(Hoechst) (Sigma) for 30 min. Cells were mounted with FluorSave™ Reagent 
mounting medium (Merck) and analyzed with a Zeiss LSM 510 Meta confocal 
microscope (Jena). 
Chemotaxis 
6x104 T24 cells were seeded on µ-Slide Chemotaxis3D (IBIDI) and allowed to attach 
for 3 h. Chemotaxis experiment (20 h) was performed as described before 
(Wiedmann et al, 2012). Cell tracking was performed with Image J plugin Manual 
tracking (Fabrice Cordelières, Institut Curie, Orsay). 30 cells were tracked per 
experiment. Data analysis was done with Chemotaxis and Migration Tool (IBIDI). 
Rayleigh test was used to describe uniformity of distribution of cell endpoints. With 
p>0.05 uniformity is rejected (Zengel et al, 2011). 
Measurement of cell death 
Flow cytometry analysis was performed as described before (Schneider et al, 2015). 
Specific cell death was calculated as follows: specific cell death = [(x – Co) / (100 – 
Co)] x 100 
Membrane staining 
2x104 HUH7 cells were seeded onto µ-slides 8-well ibidiTreat. For membrane 
labeling, the PKH 26 red fluorescent cell linker mini kit was used (Sigma). After 
treatment, cells were incubated with the dye according to the manufacturer’s 
instructions for 2 min. After removal, cells were incubated with pure FCS for 1 min 
followed by an incubation of 2 h in medium. Cells were then fixed with PFA and 
 stained with Hoechst for 10 min. Washed cells were mounted in FluorSave™ 
Reagent mounting medium and cells were analyzed by confocal microscopy. 
Lysotracker staining 
2x104 T24 cells were seeded onto µ-slides 8-well ibidiTreat and stimulated. 
Thereafter, cells were incubated for 30 min with 1 µM Lysotracker® Red DND-99 
(Molecular Probes®) and Hoechst in PBS. After removal, pictures were taken 
immediately with a Zeiss LSM 510 Meta confocal microscope. 
Measurement of intracellular calcium 
Calcium measurement was performed as described before (Grimm et al, 2014). 
Briefly, 3x104 T24 cells were seeded onto µ-slides 8-well ibidiTreat and were 
stimulated the next day. Then, cells were loaded with 4 μM fura-2AM (Invitrogen) for 
1 h in a standard bath solution (see ref.). After that, cells were washed with 2 mM 
EGTA for 30 min. Cells were imaged in the presence of 2 mM EGTA. An Axiovert200 
microscope (Zeiss), IMAGO-QE and Polychrome V (TILL Photonics GmbH) were 
used for measurement. 
β1-integrin internalization 
1x104 T24 cells were seeded onto µ-slides 8-well ibidiTreat and stimulated. Cells 
were starved for 90 min and stained with β1-integrin (TS2/16) (Santa Cruz) in cold 
0.01% BSA/DMEM without FCS for 45 min at 4 °C. Washed cells were incubated 
with 0.01% BSA/DMEM with FCS for 1 h at 37 °C. Next, 1 μM phorbol 12-myristat 
13-acetat (Merck) in 0.01% BSA/ DMEM with FCS was added for 30 min at 37 °C. 
After washing and fixing cells with PFA, 0.1% Triton-X100 was added. AlexaFlour 
488-goat-antimouse (Molecular Probes®) and Hoechst were used for 1 h to stain 
cells. Washed cells were embedded in FluorSave™ Reagent mounting medium and 
analyzed by confocal microscopy. 
 Immunocytochemistry 
1x104 T24 cells were seeded onto µ-slides 8-well ibidiTreat (IBIDI). Treated and PFA 
fixed cells were permeabilized with 0.2% Triton X-100/PBS. Hereafter, unspecific 
binding sites were blocked with 1% BSA/PBS containing 0.1% Triton X-100. 
Antibodies were diluted in blocking solution. Used antibodies are given below: β1-
integrin (TS2/16), EEA1, LAMP3 (Santa Cruz). Nuclei were stained with Hoechst. 
Cells were embedded in FluorSave™ Reagent mounting medium and analyzed by 
confocal microscopy. 
Staining of migrating cells 
A confluent T24 cell layer was scratched with a pipette tip, after treatment. Cells were 
allowed to migrate for 5 h and subsequently fixed with PFA. Samples were stained as 
described in section immunocytochemistry. Antibodies given below were used: β1-
integrin (TS2/16), vinculin (Santa Cruz), pFAKSr732, pSrcpY418 (Invitrogen), AlexaFluor 
680-goat-antirabbit and AlexaFluor 643-goat-antimouse (Molecular Probes®). 
Rhodamine-phalloidin was used to stain actin, Hoechst for nuclei. 
Western blot 
Western blot was performed as described before (Schneider et al, 2015). Following 
antibodies were used: β1-integrin (TS2/16), FAK (Santa Cruz), pFAKSr732, pSrcpY418 
(Molecular Probes®), Src (L4A1) (Cell Signalling), actin (Millipore), HRP-goat-
antirabbit (Bio-Rad) and HRP-goat-antimouse (Santa Cruz). 
In vivo mouse model 
4T1-Luc cells were pretreated with 10 µM tetrandrine or DMSO for 24 h. Female 
BALB/cOlaHsd mice (Harlan) were inoculated with 1x105 4T1-Luc cells via the tail 
vein. After five days, imaging of the mice was performed using the IVIS Lumina 
system with Living Image software 4.4 (Caliper Life Sciences) 15 min after 
 intraperitoneal injection of 6 mg Na-luciferin (PerkinElmer). The total signal per 
defined region of interest was calculated as photons/second/cm2 (total flux/area). 
Animal experiments were approved by the District Government of Upper Bavaria in 
accordance with the German animal welfare and institutional guidelines. 
Statistical analysis 
GraphPad Prism Software was used for all statistical analysis. In some experiments 
data were normalized to control or as indicated. 
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 THE PAPER EXPLAINED 
PROBLEM: Cancer is a leading cause of death worldwide. Most cancer-related 
deaths are due to metastasis. To colonize distant sites, cancer cells are highly 
dependent on their ability to migrate. Disrupting this process is thought to be a 
promising approach for new anti-cancer drugs.  
RESULTS: Here we show that function of recently identified Ca2+-permeable 
endolysosomal two pore channels (TPCs) is crucial for cancer cell motility. 
Pharmacological inhibition of these channels abrogated migration of invasive cancer 
cells in vitro and in vivo. Moreover, we provide evidence for the underlying molecular 
mechanisms as integrin recycling was disturbed.  
IMPACT: Our study suggests TPCs as promising new targets for the treatment of 
metastatic cancers. 
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 FIGURE LEGENDS 
Fig.1: TPCs in cancer cells. (A, B) mRNA levels of TPC2 and TPC1 in different 
cancer cell lines was assessed by qRT-PCR using the SYBR Green PCR Master 
Mix. Expression level of MDA-MB-231 cells was set 1. Bars are the SEM of three 
independent experiments performed in duplet. (C) Human liver sections (HCC and 
surrounding tissue) were stained with an antibody against TPC2. Counterstaining 
was done with hematoxylin. One representative specimen is shown. (D) Cartoon 
illustrating whole-endolysosomal patch clamp method. (E) Representative current-
voltage relation recorded from a vacuolin-enlarged endolysosomal vesicle manually 
isolated from cultured T24 cells. Shown are the effect of 1 μM PI(3,5)P2, and the 
blocking effect of 500 nM tetrandrine. (F) Population data for current amplitudes at -
100 mV obtained from experiments as shown in A; p*<0.05, Student’s t-test, data are 
shown as mean ±SEM. 
Fig.2: Silencing of TPC1 and TPC2 leads to reduced migration and adhesion in 
cancer cells. For all experiments T24 cells were silenced with siRNA against TPC1 
and TPC2 for 72 h. (A) siRNA-treated cells were allowed to migrate in Transwell® 
chambers for 16 h. (B) qPCR analysis of TPC1 and TPC2 mRNA levels were 
assessed with the SYBR Green PCR Master Mix. Bars are the SEM of three 
independent experiments performed in duplet. (C) After silencing, cells were allowed 
to adhere for 1 h, fixed and stained (rhodamine-phalloidin, Hoechst). Cells were 
analyzed by confocal microscopy. Scale bars, 150 µm. (A, C) Bars are the SEM of 
three independent experiments, p*<0.05 (One-way ANOVA, Dunnett’s multiple 
comparison test). (D) Movement of silenced T24 cells along a FCS gradient was 
monitored (20 h) by live cell imaging and analyzed for directed migration (pValue) 
 and velocity (Image-J, IBIDI software). Dashed line indicates p=0.05. Bars are the 
SEM of three independent experiments, p*<0.05 (t-test). 
Fig.3: Ned-19 and tetrandrine inhibit cancer cell migration. (A, B) T24, HUH7 
and 4T1 cells were pretreated with Ned-19 and tetrandrine for 8 h (T24: 250 µM Ned-
19, 15 µM Tet; HUH7: 150 µM Ned-19, 2,5 µM Tet; 4T1: 10 µM Tet). Cells were 
allowed to migrate in Transwell® chambers for 16 h in the presence of the inhibitor. 
Bars are the SEM of three independent experiments, p*<0.05 (t-test). (C) Cell death 
was assessed after 24 h of treatment with inhibitors used in A and B by flow 
cytometry analysis. Means of three independent experiments performed in triplicate 
±SEM is displayed. 
Fig.4: Inhibition of TPCs disrupts endocytic recycling presumably through 
disturbed Ca2+ signaling. (A) Membranes were stained with PKH 26 red in HUH7 
cells after 24 h of Ned-19 (150 µM) treatment. Cells were allowed to recycle again for 
2 h. Fixed cells were analyzed by confocal microscopy. (B) Ned-19-treated T24 cells 
(250 µM, 24 h) were stained with Lysotracker® Red DND-99 and analyzed by 
confocal microscopy. (A, B) Nuclei were stained with Hoechst (blue). Vesicles were 
analyzed with Image J. Bars are the SEM of three independent experiments, p*<0.05 
(t-test). Scale bars, 20µm. (C) Intracellular calcium levels were measured with fura-
2AM in T24 cells. Cells were pretreated with 15 µM tetrandrine (5 h) and loaded with 
fura-2AM. Calcium imaging was performed in Ca2+-free EGTA buffer. Nigericin was 
used to release Ca2+ from the endolysosomal system. One representative experiment 
is shown. Bars are the SEM of five independent experiments (with 9-16 cells, each), 
p*<0.05 (t-test). 
Fig.5: β1-integrin recycling is hindered after TPC inhibition. (A) Internalized β1-
integrin was stained in T24 cells after 24 h of Ned-19 treatment (250 µM). Scale bars, 
 20 µm (upper pictures) and 10 µm (lower pictures). (B) Ned-19-treated T24 cells (250 
µM, 24 h) were stained for β1-integrin, EEA1, LAMP3 and nuclei with Hoechst (blue). 
Scale bars, 10 µm. (A, B) Pictures of cells were taken with confocal microscopy. (A) 
Vesicles were analyzed with Image J. Bars are the SEM of three independent 
experiments, p*<0.05 (t-test). 
Fig.6: TPC function is required for formation of leading edges. (A) T24 cells 
were scratched and let migrate for 5 h after a pretreatment with 250 µM Ned-19 for 
16 h. Fixed cells were stained for actin, β1-integrin, pSrc, pFAK and vinculin. One 
representative picture out of three independent experiments is shown. Scale bars, 20 
µm. (B) Total protein amounts of β1-integrin, pSrc, Src, pFAK and FAK were 
detected by western blot analysis in T24 cells after treatment with 250 µM Ned-19 for 
24 h. One representative blot is shown. Quantification was done with Image J. Bars 
are the SEM of three independent experiments. 
Fig.7: Inhibition of TPC function in 4T1-Luc cells reduces the formation of lung 
metastasis in vivo. 1x105 4T1-Luc cells, pretreated with 10 µM tetrandrine or 
respectively DMSO, were injected intravenously into BALB/cOlaHsd mice. On day 
five after cell inoculation bioluminescence signals were measured by imaging the 
mice ventrodorsal. The total signal per defined region of interest was calculated as 
photons/second/cm2 (total flux/area). Bars are the SEM, p*<0.05 (t-test). 
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